High Cost Drugs
Click here to download the Kent and Medway Health Economy National Tariff Excluded Drugs Manual
Also known as the High Cost Drugs (HCD) Manual. Last updated: Oct 2024
The purpose of this manual is to describe the process for funding high cost drugs or devices excluded from the National Tariff payment system, (previously known as National Tariff Exclusions). These drugs or devices are only commissioned for those indications listed under the individual drug. With regard to items commissioned by ICB, drugs or devices may not be commissioned across every ICB.
Drugs or devices may not be commissioned across every ICB. Information on whether a ICB has commissioned a drug can be found in the “Commissioner” column in the manual. Blueteq forms must be completed in all cases. Invoices will be refused for indications not listed within this manual.
If a drug is being requested to treat a patient for an indication/condition NOT listed in the manual then an Individual Funding Request (IFR) or Business Case must be made to either the ICB or NHS England depending on who currently commissions the drug for other uses. IFR requests may be made for rare diseases or exceptional circumstances. A business case would be required where it is expected or foreseeable that there is a cohort of patients affected. Please contact the named individual at the front of the manual (link above) for preliminary advice on whether an IFR or business case is required.
|
The tables below contain a summary of the high cost drugs, for full details please see the entries within the ICB manual and NHSE manual.
Drug Name | Indication | Commissioner |
3,4-DIAMINOPYRIDINE | LAMBERT-EATON MYASTHENIC SYNDROME (LEMS) | NHS ENGLAND |
ABACAVIR | HIV IN COMBINATION WITH OTHER ANTI-RETROVIRAL DRUGS | NHS ENGLAND |
ABALOPARATIDE | MALE AND JUVENILE OSTEOPOROSIS HYPOPARATHYROIDISM |
NHS ENGLAND |
Abaloparatide (Eladynos®) | Osteoporosis | ICB |
ABATACEPT | JUVENILE IDIOPATHIC ARTHRITIS - PAEDIATRICS | NHS ENGLAND |
ABATACEPT | JUVENILE IDIOPATHIC ARTHRITIS - PAEDIATRICS | NHS ENGLAND |
ABATACEPT | REFRACTORY IDIOPATHIC INFLAMMATORY MYOPATHIES | NHS ENGLAND |
ABATACEPT | SEVERE TREATMENT-RESISTANT MORPHOEA (LOCALISED SCLERODERMA) | NHS ENGLAND |
Abatacept (Orencia®) | Rheumatoid arthritis (1st line biologic ) | ICB |
Abatacept (Orencia®) | Rheumatoid Arthritis (2nd line biologic) | ICB |
Abatacept (Orencia®) | Juvenile Idiopathic arthritis (adult only) | ICB |
ABEMACICLIB | CANCER Breast cancer |
NHS ENGLAND |
ABEMACICLIB | CANCER Breast cancer |
NHS ENGLAND |
ABEMACICLIB | CANCER Breast cancer |
NHS ENGLAND |
ABIRATERONE | CANCER Prostate cancer |
NHS ENGLAND |
ABIRATERONE | CANCER Prostate cancer |
NHS ENGLAND |
ABIRATERONE | CANCER Prostate cancer |
NHS ENGLAND |
ABIRATERONE | CANCER Prostate cancer |
NHS ENGLAND |
ABIRATERONE | CANCER Prostate cancer |
NHS ENGLAND |
ABROCITINIB | MODERATE TO SEVERE ATOPIC DERMATITIS - PAEDIATRICS | NHS ENGLAND |
Abrocitinib (Cibinqo®) | Moderate to severe atopic dermatitis | ICB |
ACALABRUTINIB | CANCER CLL |
NHS ENGLAND |
ACORAMIDIS | AMYLOIDOSIS | NHS ENGLAND |
ADALIMUMAB | BEHCETS SYNDROME | NHS ENGLAND |
ADALIMUMAB | HIDRADENITIS SUPPURATIVA | NHS ENGLAND |
ADALIMUMAB | JUVENILE IDIOPATHIC ARTHRITIS - PAEDIATRICS | NHS ENGLAND |
ADALIMUMAB | JUVENILE IDIOPATHIC ARTHRITIS - PAEDIATRICS | NHS ENGLAND |
ADALIMUMAB | NON BACTERIAL OSTEOMYELITIS/OSTEITIS | NHS ENGLAND |
ADALIMUMAB | PLAQUE PSORIASIS - PAEDIATRICS | NHS ENGLAND |
ADALIMUMAB | UVEITIS - ADULTS | NHS ENGLAND |
Adalimumab (Humira®, Imraldi®, Amgevita®, Yuflyma®) | Ankylosing Spondylitis and Axial Spondyloarthritis | ICB |
Adalimumab (Humira®, Imraldi®, Amgevita®, Yuflyma®) | Chrohn’s Disease(1st and 2nd line biologic) | ICB |
Adalimumab (Humira®, Imraldi®, Amgevita®, Yuflyma®) | Psoriasis | ICB |
Adalimumab (Humira®, Imraldi®, Amgevita®, Yuflyma®) | Psoriatic Arthritis | ICB |
Adalimumab (Humira®, Imraldi®, Amgevita®, Yuflyma®) | Rheumatoid arthritis (1st line biologic ) | ICB |
Adalimumab (Humira®, Imraldi®, Amgevita®, Yuflyma®) | Rheumatoid Arthritis (2nd line biologic) | ICB |
Adalimumab (Humira®, Imraldi®, Amgevita®, Yuflyma®) | Juvenile idiopathic arthritis (adult) | ICB |
Adalimumab (Humira®, Imraldi®, Amgevita®, Yuflyma®) | Ulcerative Colitis (moderate to severe) | ICB |
ADUCANUMAB | ALZHEIMERS DISEASE - YOUNG ONSET DEMENTIA | NHS ENGLAND |
AFAMELANOTIDE | ERYTHROPOIETIC PROTOPORPHYRIA | NHS ENGLAND |
AFAMITRESGENE AUTOLEUCEL | CANCER Sarcoma |
NHS ENGLAND |
AFATINIB | CANCER Lung cancer |
NHS ENGLAND |
AFLIBERCEPT | CANCER Colorectal cancer |
NHS ENGLAND |
Aflibercept (Eylea®) | Macular degeneration(wet age-related) | ICB |
Aflibercept (Eylea®) | Diabetic macular oedema | ICB |
Aflibercept (Eylea®) | Choroidal Neovascularisation | ICB |
Aflibercept (Eylea®) | Macular Oedema after BRVO(Branch Retinal Vein Occlusion) | ICB |
Aflibercept (Eylea®) | Macular Oedema secondary to central retinal vein occlusion | ICB |
AGALSIDASE ALFA | FABRY'S DISEASE | NHS ENGLAND |
AGALSIDASE BETA | FABRY'S DISEASE | NHS ENGLAND |
ALBUTREPENONACOG ALFA (FACTOR IX - recombinant) |
HAEMOPHILIA B | NHS ENGLAND |
ALDESLEUKIN | CANCER | NHS ENGLAND |
ALECTINIB | CANCER Lung cancer |
NHS ENGLAND |
ALECTINIB | CANCER Lung cancer |
CDF |
ALECTINIB | CANCER Lung cancer |
NHS ENGLAND |
ALEMTUZUMAB | BEHCETS SYNDROME | NHS ENGLAND |
ALEMTUZUMAB | CANCER CLL |
NHS ENGLAND |
ALEMTUZUMAB | MULTIPLE SCLEROSIS | NHS ENGLAND |
ALEMTUZUMAB | MULTIPLE SCLEROSIS | NHS ENGLAND |
ALEMTUZUMAB | PRE-TRANSPLANT IMMUNOSUPPRESSION | NHS ENGLAND |
ALGLUCOSIDASE ALFA | POMPE DISEASE | NHS ENGLAND |
Alirocumab (Praluent®) | Primary hypercholesterolaemia or mixed dyslipidaemia | ICB |
Alirocumab (Praluent®) | Primary heterozygous-familial hypercholesterolaemia | ICB |
Alitretinoin (Toctino®) | Eczema (chronic) | ICB |
ALPELISIB | CANCER CML |
NHS ENGLAND |
AMBRISENTAN | PULMONARY ARTERIAL HYPERTENSION | NHS ENGLAND |
AMIFAMPRIDINE PHOSPHATE | LAMBERT-EATON MYASTHENIC SYNDROME (LEMS) | NHS ENGLAND |
AMIKACIN INHALATION | CYSTIC FIBROSIS | NHS ENGLAND |
AMIKACIN LIPOSOMAL (INHALED) | CYSTIC FIBROSIS | NHS ENGLAND |
AMIKACIN LIPOSOMAL (INHALED) | NON-TUBERCULOUS MYCOBACTERIAL PULMONARY DISEASE DUE TO MYCOBACTERIUM AVIUM COMPLEX (MAC) | NHS ENGLAND |
AMIVANTAMAB | CANCER | NHS ENGLAND |
AMPHOTERICIN LIPOSOMAL | FUNGAL INFECTION | NHS ENGLAND |
ANAKINRA | ADULT ONSET STILL'S DISEASE | NHS ENGLAND |
ANAKINRA | CASTLEMAN'S DISEASE | NHS ENGLAND |
ANAKINRA | CRYOPYRIN ASSOCIATED PERIODIC SYNDROME | NHS ENGLAND |
ANAKINRA | HAEMOPHAGOCYTIC LYMPHOHISTIOCYTOSIS (HLH) | NHS ENGLAND |
ANAKINRA | JUVENILE IDIOPATHIC ARTHRITIS - PAEDIATRICS | NHS ENGLAND |
ANAKINRA | JUVENILE IDIOPATHIC ARTHRITIS - PAEDIATRICS | NHS ENGLAND |
ANAKINRA | PERIODIC FEVERS AND AUTOINFLAMMATORY CONDITIONS | NHS ENGLAND |
Andexanet alfa (Andexxa®) | Anticoagulation reversal from apixaban or rivaroxaban | ICB |
ANIDULAFUNGIN | FUNGAL INFECTION | NHS ENGLAND |
ANIFROLUMAB | SYSTEMIC LUPUS ERYTHEMATOSUS (SLE) | NHS ENGLAND |
ANTILYMPHOCYTE GLOBULIN | APLASTIC ANAEMIA ORGAN TRANSPLANT |
NHS ENGLAND |
ANTITHROMBIN III | AS PER BCSH GUIDELINES FOR SPECIALISED INDICATIONS | NHS ENGLAND |
ANTITHYMOCYTE IMMUNOGLOBULIN | APLASTIC ANAEMIA ORGAN TRANSPLANT |
NHS ENGLAND |
APADAMTASE ALFA | THROMBOTIC THROMBOCYTOPENIC PURPURA | NHS ENGLAND |
APALUTAMIDE | CANCER Prostate cancer |
NHS ENGLAND |
APALUTAMIDE | CANCER Prostate cancer |
NHS ENGLAND |
Apremilast (Otezla®) | Psoriatic Arthritis | ICB |
Apremilast (Otezla®) | Moderate to severe plaque psoriasis | ICB |
ARIMOCLOMOL | NIEMANN-PICK DISEASE | NHS ENGLAND |
ARSENIC TRIOXIDE | CANCER APML |
NHS ENGLAND |
ARSENIC TRIOXIDE | CANCER APML (high risk) |
NHS ENGLAND |
ASCIMINIB | CANCER CML |
NHS ENGLAND |
ASFOTASE ALFA | HYPOPHOSPHATASIA | NHS ENGLAND |
ATACICEPT | SYSTEMIC LUPUS ERYTHEMATOSUS (SLE) | NHS ENGLAND |
ATALUREN | DUCHENNE MUSCULAR DYSTROPHY | NHS ENGLAND |
ATAZANAVIR | HIV IN COMBINATION WITH OTHER ANTI-RETROVIRAL DRUGS | NHS ENGLAND |
ATEZOLIZUMAB | CANCER Breast cancer |
NHS ENGLAND |
ATEZOLIZUMAB | CANCER Hepatocellular carcinoma |
NHS ENGLAND |
ATEZOLIZUMAB | CANCER Lung cancer |
NHS ENGLAND |
ATEZOLIZUMAB | CANCER Lung cancer |
NHS ENGLAND |
ATEZOLIZUMAB | CANCER Lung cancer |
NHS ENGLAND |
ATEZOLIZUMAB | CANCER Lung cancer |
NHS ENGLAND |
ATEZOLIZUMAB | CANCER Lung cancer |
CDF |
ATEZOLIZUMAB | CANCER Urothelial cancer |
NHS ENGLAND |
ATEZOLIZUMAB | CANCER Urothelial carcinoma |
NHS ENGLAND |
ATIDARSAGENE AUTOTEMCEL | METACHROMATIC LEUKODYSTROPHY (MLD) | NHS ENGLAND |
Atogepant (Aquipta®) | preventing migraine | ICB |
AUTOLOGOUS & ALLOGENIC SERUM EYE DROPS | SEVERE OCULAR SURFACE DISEASE | NHS ENGLAND |
AUTOLOGOUS ANTI-CD19-TRANSDUCED CD3+ CELLS - KTE-X19 | CANCER Mantle cell lymphoma |
CDF |
AUTOLOGOUS HUMAN CHONDROCYTE IMPLANTATION | ARTICULAR CARTILAGE DEFECT | NHS ENGLAND |
AUTOLOGOUS HUMAN CHONDROCYTE IMPLANTATION | ARTICULAR CARTILAGE DEFECT | NHS ENGLAND |
AUTOLOGOUS LENTIVIRAL WAS STEM CELL THERAPY | PRIMARY IMMUNODEFICIENCY - WISKOTT ALDRICH SYNDROME | NHS ENGLAND |
AVACOPAN | GRANULOMATOSIS | NHS ENGLAND |
AVALGLUCOSIDASE ALFA | GLYCOGEN STORAGE DISEASE TYPE II (POMPE DISEASE) | NHS ENGLAND |
AVALOTCAGENE ONTAPRVOVEC | ORNITHINE CARBAMOYL TRANSFERASE DEFICIENCY | NHS ENGLAND |
AVAPRITINIB | CANCER Gastrointestinal stromal tumour |
NHS ENGLAND |
AVAPRITINIB | CANCER Mastocytosis |
CDF |
AVAPRITINIB | CANCER Mastocytosis |
NHS ENGLAND |
Avatrombopag (Doptelet®) | Primary chronic immune thrombocytopenia | ICB |
Avatrombopag (Doptelet®) | Thrombocytopenia in people with chronic liver disease | ICB |
AVELUMAB | CANCER Merkel cell carcinoma |
NHS ENGLAND |
AVELUMAB | CANCER Merkel cell carcinoma |
NHS ENGLAND |
AVELUMAB | CANCER Renal cell carcinoma |
CDF |
AVELUMAB | CANCER Urothelial cancer |
NHS ENGLAND |
AXICABTAGENE CILOLEUCEL | CANCER B-cell lymphoma |
CDF |
AXICABTAGENE CILOLEUCEL | CANCER B-cell lymphoma |
NHS ENGLAND |
AXITINIB | CANCER Renal cell carcinoma |
NHS ENGLAND |
AZACITIDINE | CANCER AML |
NHS ENGLAND |
AZACITIDINE | CANCER AML |
NHS ENGLAND |
AZACITIDINE | CANCER CMML / AML |
NHS ENGLAND |
AZATHIOPRINE | TRANSPLANT IMMUNOSUPPRESSION ONLY | NHS ENGLAND |
AZTREONAM LYSINE | CYSTIC FIBROSIS | NHS ENGLAND |
AZTREONAM LYSINE | CYSTIC FIBROSIS (CONTINUOUS TREATMENT) | NHS ENGLAND |
BARDOXOLONE METHYL | CKD CAUSED BY ALPORT SYNDROME | NHS ENGLAND |
BARICITINIB | MONOGENIC INTERFERONOPATHIES | NHS ENGLAND |
Baricitinib (Olumiant®) | Moderate to severe atopic dermatitis | ICB |
Baricitinib (Olumiant®) | Rheumatoid Arthritis | ICB |
BASILIXIMAB | KIDNEY TRANSPLANT - ADULTS | NHS ENGLAND |
BASILIXIMAB | KIDNEY TRANSPLANT - CHILDREN & YOUNG PEOPLE | NHS ENGLAND |
BECLABUVIR | HEPATITIS C | NHS ENGLAND |
BEDAQUILINE | TB | NHS ENGLAND |
BEDAQUILINE | TB | NHS ENGLAND |
BEGELOMAB | GRAFT VERSUS HOST DISEASE | NHS ENGLAND |
BELANTAMAB MAFODOTIN | CANCER MM |
NHS ENGLAND |
BELATACEPT | KIDNEY TRANSPLANT - ADULTS | NHS ENGLAND |
BELATACEPT | KIDNEY TRANSPLANT - CHILDREN & YOUNG PEOPLE | NHS ENGLAND |
BELIMUMAB | SYSTEMIC LUPUS ERYTHEMATOSUS (SLE) | NHS ENGLAND |
BELUMOSUDIL | GRAFT VERSUS HOST DISEASE | NHS ENGLAND |
BELUMOSUDIL | GRAFT VERSUS HOST DISEASE | NHS ENGLAND |
BELZUTIFAN | CANCER | NHS ENGLAND |
BELZUTIFAN | CANCER Tumours associated with von Hippel-Lindau disease |
CDF |
BENDAMUSTINE | CANCER CLL |
NHS ENGLAND |
BENDAMUSTINE | CANCER Follicular lymphoma |
NHS ENGLAND |
BENDAMUSTINE | CANCER HL |
NHS ENGLAND |
BENDAMUSTINE | CANCER MCL |
NHS ENGLAND |
BENDAMUSTINE | CANCER MCL |
NHS ENGLAND |
BENDAMUSTINE | CANCER MM |
NHS ENGLAND |
BENDAMUSTINE | CANCER NHL |
NHS ENGLAND |
BENRALIZUMAB | ASTHMA | NHS ENGLAND |
BEROTRALSTAT | HEREDITARY ANGIOEDEMA - PROPHYLACTIC TREATMENT | NHS ENGLAND |
BETAINE | HOMOCYSTINURIA | NHS ENGLAND |
BEVACIZUMAB | CANCER Cervical cancer |
NHS ENGLAND |
BEVACIZUMAB | CANCER Colorectal cancer |
NHS ENGLAND |
BEVACIZUMAB | CANCER Colorectal cancer |
NHS ENGLAND |
BEVACIZUMAB | CANCER Colorectal cancer |
NHS ENGLAND |
BEVACIZUMAB | CANCER Lung cancer |
NHS ENGLAND |
BEVACIZUMAB | CANCER Ovarian, fallopian tube and peritoneal cancer |
NHS ENGLAND |
BEVACIZUMAB | NEUROFIBROMATOSIS | NHS ENGLAND |
Bevacizumab (Avastin®) | Choroidal neovascularisation (CNV) due to causes other than age-related macular degeneration (AMD) or pathological myopia (PM) | ICB |
BICTEGRAVIR | HIV IN COMBINATION WITH OTHER ANTI-RETROVIRAL DRUGS | NHS ENGLAND |
BICTEGRAVIR | HIV IN COMBINATION WITH OTHER ANTI-RETROVIRAL DRUGS | NHS ENGLAND |
BIMAGRUMAB | INCLUSION BODY MYOSITIS | NHS ENGLAND |
Bimekizumab (Bimzelx®) | Psoriatic Arthritis | ICB |
Bimekizumab (Bimzelx®) | Axial spondyloarthritis | ICB |
Bimekizumab (Bimzelx®) | Psoriasis | ICB |
BINIMETINIB | CANCER Melanoma |
NHS ENGLAND |
BIOTIN | MULTIPLE SCLEROSIS | NHS ENGLAND |
BIRCH BARK EXTRACT | EPIDERMOLYSIS BULLOSA | NHS ENGLAND |
BIS-CHOLINE TETRATHIOMOLYBDATE | WILSON'S DISEASE | NHS ENGLAND |
BIZALIMOGENE RALAPLASMID | CERVICAL DYSPLASIA | NHS ENGLAND |
BLINATUMOMAB | CANCER ALL |
NHS ENGLAND |
BLINATUMOMAB | CANCER ALL |
NHS ENGLAND |
BORTEZOMIB | CANCER Amyloid light-chain amyloidosis |
NHS ENGLAND |
BORTEZOMIB | CANCER MM |
NHS ENGLAND |
BORTEZOMIB | CANCER MCL |
NHS ENGLAND |
BORTEZOMIB | CANCER MCL |
NHS ENGLAND |
BORTEZOMIB | CANCER MM |
NHS ENGLAND |
BORTEZOMIB | CANCER MM |
NHS ENGLAND |
BORTEZOMIB | CANCER MM |
NHS ENGLAND |
BORTEZOMIB | CANCER MM |
CDF |
BORTEZOMIB | CANCER MM |
NHS ENGLAND |
BORTEZOMIB | CANCER Waldenstrom's macroglobulinaemia |
NHS ENGLAND |
BORTEZOMIB | ORGAN REJECTION POST KIDNEY TRANSPLANT | NHS ENGLAND |
BOSENTAN | DIGITAL ULCERS | NHS ENGLAND |
BOSENTAN | PULMONARY ARTERIAL HYPERTENSION | NHS ENGLAND |
BOSUTINIB | CANCER CML |
NHS ENGLAND |
BOTARETIGENE SPAROPARVOVEC | RETINAL DISORDERS | NHS ENGLAND |
BRAIN CANCER VACCINE | CANCER | NHS ENGLAND |
BRENTUXIMAB | CANCER HL |
NHS ENGLAND |
BRENTUXIMAB | CANCER Lymphoma |
NHS ENGLAND |
BRENTUXIMAB | CANCER Lymphoma |
NHS ENGLAND |
BRENTUXIMAB | CANCER Lymphoma |
NHS ENGLAND |
BREXUCABTAGENE AUTOLEUCEL | CANCER ALL |
CDF |
BRIGATINIB | CANCER Lung cancer |
NHS ENGLAND |
BRIGATINIB | CANCER Lung cancer |
NHS ENGLAND |
BRIMAPITIDE | ACUTE SENSORINEURAL HEARING LOSS | NHS ENGLAND |
Brodalumab (Kyntheum®) | Moderate to severe plaque psoriasis | ICB |
Brolucizumab (Beovu®) | Diabetic macular oedema | ICB |
Brolucizumab (Beovu®) | Macular degeneration(wet age-related) | ICB |
BULEVIRTIDE | COMPENSATED LIVER DISEASE | NHS ENGLAND |
BUROSUMAB | X LINKED HYPOPHOSPHATAEMIA | NHS ENGLAND |
BUROSUMAB | X LINKED HYPOPHOSPHATAEMIA | NHS ENGLAND |
C1 ESTERASE INHIBITORS | HEREDITARY ANGIOEDEMA - ACUTE TREATMENT | NHS ENGLAND |
C1 ESTERASE INHIBITORS | HEREDITARY ANGIOEDEMA - PROPHYLACTIC TREATMENT | NHS ENGLAND |
C1 ESTERASE INHIBITORS | HEREDITARY ANGIOEDEMA - PROPHYLACTIC TREATMENT IN CHILDREN (CINRYZE ONLY) | NHS ENGLAND |
CABAZITAXEL | CANCER Prostate cancer |
NHS ENGLAND |
CABOTEGRAVIR | HIV IN COMBINATION WITH OTHER ANTI-RETROVIRAL DRUGS | NHS ENGLAND |
CABOTEGRAVIR | HIV IN COMBINATION WITH OTHER ANTI-RETROVIRAL DRUGS | NHS ENGLAND |
CABOZANTINIB | CANCER Thyroid cancer |
NHS ENGLAND |
CABOZANTINIB | CANCER Hepatocellular cancer |
NHS ENGLAND |
CABOZANTINIB | CANCER Renal cell carcinoma |
NHS ENGLAND |
CABOZANTINIB | CANCER Renal cell carcinoma |
NHS ENGLAND |
CABOZANTINIB | CANCER Renal cell carcinoma |
NHS ENGLAND |
CALCIFEDIOL | HYPERPARATHYROIDISM IN RENAL DIALYSIS PATIENTS | NHS ENGLAND |
CALCIUM, MAGNESIUM, POTASSIUM + SODIUM OXYBATE | NARCOLEPSY - PAEDIATRICS | NHS ENGLAND |
CANAKINUMAB | CRYOPYRIN ASSOCIATED PERIODIC SYNDROME | NHS ENGLAND |
CANAKINUMAB | JUVENILE IDIOPATHIC ARTHRITIS - PAEDIATRICS | NHS ENGLAND |
CANAKINUMAB | PERIODIC FEVER SYNDROMES: TRAPS, HIDS/MKD and FMF | NHS ENGLAND |
CANAKINUMAB | STILL'S DISEASE | NHS ENGLAND |
CANNABIDIOL | DRAVET SYNDROME | NHS ENGLAND |
CANNABIDIOL | LENNOX-GASTAUT SYNDROME | NHS ENGLAND |
CANNABIDIOL | TUBEROUS SCLEROSIS SYNDROME | NHS ENGLAND |
CANPULDENCEL-T | CANCER Glioblastoma |
NHS ENGLAND |
CAPLACIZUMAB | THROMBOTIC THROMBOCYTOPENIC PURPURA | NHS ENGLAND |
CAPMATINIB | CANCER Lung cancer |
NHS ENGLAND |
CARFILZOMIB | CANCER MM |
NHS ENGLAND |
CARFILZOMIB | CANCER MM |
NHS ENGLAND |
CARGLUMIC ACID | UREA CYCLE DISORDERS | NHS ENGLAND |
CARNITINE | CARNITINE DEFICIENCY | NHS ENGLAND |
CASPOFUNGIN | FUNGAL INFECTION | NHS ENGLAND |
CATRIDECACOG (FACTOR XIII - recombinant) |
AS PER BCSH GUIDELINES FOR SPECIALISED INDICATIONS | NHS ENGLAND |
CEMIPLIMAB | CANCER Skin cancer |
NHS ENGLAND |
CEMIPLIMAB | CANCER Cervical cancer |
NHS ENGLAND |
CENEGERMIN | NEUROTROPHIC KERATITIS | NHS ENGLAND |
CERITINIB | CANCER Lung cancer |
NHS ENGLAND |
CERITINIB | CANCER Lung cancer |
NHS ENGLAND |
CERLIPONASE ALFA | NEURONAL CEROID LIPOFUSCINOSIS | NHS ENGLAND |
Certolizumab pegol (Cimzia®) | Rheumatoid Arthritis | ICB |
Certolizumab pegol (Cimzia®) | Moderate to severe plaque psoriasis | ICB |
Certolizumab pegol (Cimzia®) | Psoriatic Arthritis | ICB |
Certolizumab pegol (Cimzia®) | Ankylosing Spondylitis and Axial Spondyloarthritis | ICB |
CETUXIMAB | CANCER Colorectal cancer |
NHS ENGLAND |
CETUXIMAB | CANCER Colorectal cancer |
NHS ENGLAND |
CETUXIMAB | CANCER Head and neck cancer |
NHS ENGLAND |
CETUXIMAB | CANCER Head and neck cancer |
NHS ENGLAND |
CHEMOTHERAPY | CANCER (NOT SPECIFICALLY LISTED) | NHS ENGLAND CDF |
CHENODEOXYCHOLIC ACID | CEREBROTENDINOUS XANTHOMATOSIS (CTX) | NHS ENGLAND |
CHENODEOXYCHOLIC ACID | PRIMARY BILIARY CIRRHOSIS | NHS ENGLAND |
CHLORMETHINE | MYCOSIS FUNGOIDES-TYPE CUTANEOUS T-CELL LYMPHOMA | NHS ENGLAND |
CHOLIC ACID | INBORN ERRORS IN PRIMARY BILE ACID SYNTHESIS | NHS ENGLAND |
CICLOSPORIN | TRANSPLANT IMMUNOSUPPRESSION ONLY | NHS ENGLAND |
CILTACABTAGENE AUTOLEUCEL | CANCER MM |
NHS ENGLAND |
CIPAGLUCOSIDASE ALFA | GLYCOGEN STORAGE DISEASE TYPE II (POMPE DISEASE) | NHS ENGLAND |
CIPROFLOXACIN INHALATION | CYSTIC FIBROSIS | NHS ENGLAND |
CIPROFLOXACIN LIPOSOMAL (INHALED) | CYSTIC FIBROSIS | NHS ENGLAND |
CLADRIBINE | MULTIPLE SCLEROSIS | NHS ENGLAND |
CLADRIBINE | PULMONARY LANGERHANS HISTIOCYTOSIS | NHS ENGLAND |
CLOFARABINE | CANCER ALL |
NHS ENGLAND |
CLOFARABINE | CANCER AML |
NHS ENGLAND |
COBICISTAT | HIV IN COMBINATION WITH OTHER ANTI-RETROVIRAL DRUGS | NHS ENGLAND |
COBICISTAT | HIV IN COMBINATION WITH OTHER ANTI-RETROVIRAL DRUGS | NHS ENGLAND |
COBICISTAT | HIV IN COMBINATION WITH OTHER ANTI-RETROVIRAL DRUGS | NHS ENGLAND |
COBIMETINIB | CANCER Melanoma |
NHS ENGLAND |
COLESTILAN | ADULT RENAL DIALYSIS ONLY | NHS ENGLAND |
COLISTIMETHATE SODIUM | CYSTIC FIBROSIS | NHS ENGLAND |
COLISTIMETHATE SODIUM | CYSTIC FIBROSIS | NHS ENGLAND |
Collagenase clostridium hystoliticum (Xiapex®) | Dupuytren’s contracture in patients with a palpable cord | ICB |
CONCIZUMAB | PREVENTION OF BLEEDING EPISODES IN HAEMOPHILIA A OR B | NHS ENGLAND |
CONESTAT ALFA | HEREDITARY ANGIOEDEMA - ACUTE TREATMENT ONLY | NHS ENGLAND |
COPPER HISTIDINATE | MENKES DISEASE | NHS ENGLAND |
CRIZOTINIB | CANCER Lung cancer |
NHS ENGLAND |
CRIZOTINIB | CANCER Lung cancer |
NHS ENGLAND |
CRIZOTINIB | CANCER Lung cancer |
NHS ENGLAND |
CROVALIMAB | PAROXYSMAL NOCTURNAL HAEMOGLOBINURIA | NHS ENGLAND |
CYSTEAMINE (MERCAPTAMINE) | NEPHROPATHIC CYSTINOSIS | NHS ENGLAND |
DABRAFENIB | CANCER Glioma |
NHS ENGLAND |
DABRAFENIB | CANCER Lung cancer |
NHS ENGLAND |
DABRAFENIB | CANCER Melanoma |
NHS ENGLAND |
DABRAFENIB | CANCER Melanoma |
NHS ENGLAND |
DABRAFENIB | CANCER Melanoma |
NHS ENGLAND |
DABRAFENIB | CANCER Thyroid cancer |
NHS ENGLAND |
DACOMITINIB | CANCER Lung cancer |
NHS ENGLAND |
DAMOCTOCOG ALFA PEGOL (FACTOR VIII - recombinant) |
HAEMOPHILIA A | NHS ENGLAND |
DANICOPAN | PAROXYSMAL NOCTURNAL HAEMOGLOBINURIA | NHS ENGLAND |
DARATUMUMAB | CANCER Amyloid light-chain amyloidosis |
NHS ENGLAND |
DARATUMUMAB | CANCER MM |
NHS ENGLAND |
DARATUMUMAB | CANCER MM |
NHS ENGLAND |
DARATUMUMAB | CANCER MM |
NHS ENGLAND |
DARATUMUMAB | CANCER MM |
NHS ENGLAND |
DARBEPOETIN ALPHA | DIALYSIS-INDUCED ANAEMIA | NHS ENGLAND |
DAROLUTAMIDE | CANCER Prostate cancer |
NHS ENGLAND |
DAROLUTAMIDE | CANCER Prostate cancer |
NHS ENGLAND |
DARUNAVIR | HIV IN COMBINATION WITH OTHER ANTI-RETROVIRAL DRUGS | NHS ENGLAND |
DASABUVIR | HEPATITIS C | NHS ENGLAND |
DASATINIB | CANCER CML |
NHS ENGLAND |
DASATINIB | CANCER CML |
NHS ENGLAND |
DECITABINE | CANCER AML |
NHS ENGLAND |
DEFERASIROX | IRON CHELATION IN THALASSAEMIA AND SICKLE CELL | NHS ENGLAND |
DEFERASIROX | IRON CHELATION IN THALASSAEMIA AND SICKLE CELL | NHS ENGLAND |
DEFERIPRONE | IRON CHELATION IN THALASSAEMIA AND SICKLE CELL | NHS ENGLAND |
DEFERIPRONE | IRON CHELATION IN THALASSAEMIA AND SICKLE CELL | NHS ENGLAND |
DEFIBROTIDE | HEPATIC VENO-OCCLUSIVE DISEASE | NHS ENGLAND |
DELAMANID | TB | NHS ENGLAND |
DELANDISTROGENE MOXAPARVOVEC | DUCHENNE MUSCULAR DYSTROPHY | NHS ENGLAND |
DESFERRIOXAMINE | IRON CHELATION IN THALASSAEMIA AND SICKLE CELL | NHS ENGLAND |
DESFERRIOXAMINE | IRON CHELATION IN THALASSAEMIA AND SICKLE CELL | NHS ENGLAND |
Deucravacitinib (Sotyktu®) | Psoriasis | ICB |
DEXAMETHASONE INTRA-ERYTHROCYTE | ATAXIA TELANGIECTASIA | NHS ENGLAND |
Dexamethasone intravitreal implant (Ozurdex®) | Macular oedema (retinal vein occlusion) | ICB |
Dexamethasone intravitreal implant (Ozurdex®) | Non-infections uveitis | ICB |
Dexamethasone intravitreal implant (Ozurdex®) | Diabetic macular oedema | ICB |
DEXRAZOXANE | ANTHRACYCLINE CARDIOTOXICITY | NHS ENGLAND |
DEXRAZOXANE | ANTHRACYCLINE EXTRAVASATION | NHS ENGLAND |
DIBOTERMIN ALFA | COMPLEX SPINAL SURGERY | NHS ENGLAND |
DIDANOSINE | HIV IN COMBINATION WITH OTHER ANTI-RETROVIRAL DRUGS | NHS ENGLAND |
DIFELIKEFALIN | PRURITUS ASSOCIATED WITH CHRONIC KIDNEY DISEASE ON HAEMODIALYSIS | NHS ENGLAND |
Digoxin immune fab (DigiFab®) | Digoxin toxicity | This drug has not been formally commissioned, however due the nature of the indication it is considered that all CCGs would fund. |
DIMETHYL FUMARATE | MULTIPLE SCLEROSIS | NHS ENGLAND |
Dimethyl Fumarate (Skilarence) | Moderate to severe plaque psoriasis | ICB |
DINUTUXIMAB BETA | CANCER Neuroblastoma |
NHS ENGLAND |
DIRLOCOCTOGENE SAMOPARVOVEC | HAEMOPHILIA A | NHS ENGLAND |
DIROXIMEL FUMARATE | MULTIPLE SCLEROSIS | NHS ENGLAND |
DOCETAXEL | CANCER Prostate cancer |
NHS ENGLAND |
DOLUTEGRAVIR | HIV IN COMBINATION WITH OTHER ANTI-RETROVIRAL DRUGS | NHS ENGLAND |
DOLUTEGRAVIR | HIV IN COMBINATION WITH OTHER ANTI-RETROVIRAL DRUGS | NHS ENGLAND |
DOLUTEGRAVIR | HIV IN COMBINATION WITH OTHER ANTI-RETROVIRAL DRUGS | NHS ENGLAND |
DOLUTEGRAVIR | HIV IN COMBINATION WITH OTHER ANTI-RETROVIRAL DRUGS | NHS ENGLAND |
DORAVIRINE | HIV IN COMBINATION WITH OTHER ANTI-RETROVIRAL DRUGS | NHS ENGLAND |
DORAVIRINE | HIV IN COMBINATION WITH OTHER ANTI-RETROVIRAL DRUGS | NHS ENGLAND |
DORNASE ALFA | CYSTIC FIBROSIS | NHS ENGLAND |
DORNASE ALFA | PRIMARY CILIARY DYSKINESIA | NHS ENGLAND |
DOSTARLIMAB | CANCER Endometrial cancer |
CDF |
DOSTARLIMAB | CANCER Endometrial cancer |
CDF |
DRUG NAME | INDICATION | COMMISSIONER |
DUPILUMAB | ASTHMA | NHS ENGLAND |
Dupilumab (Dupixent®) | Moderate to severe atopic dermatitis after topical treatments | ICB |
DURVALUMAB | CANCER Lung cancer |
NHS ENGLAND |
DURVALUMAB | CANCER Lung cancer |
CDF |
DURVALUMAB | CANCER Biliary tract cancer |
NHS ENGLAND |
DUVELISIB | CANCER CLL |
NHS ENGLAND |
DUVELISIB | CANCER Follicular lymphoma |
NHS ENGLAND |
ECALLANTIDE | HEREDITARY ANGIOEDEMA - ACUTE TREATMENT ONLY | NHS ENGLAND |
ECULIZUMAB | AHUS | NHS ENGLAND |
ECULIZUMAB | C3 GLOMERULOPATHY (POST TRANSPLANT) | NHS ENGLAND |
ECULIZUMAB | DELAYED HAEMOLYTIC TRANSFUSION REACTIONS AND HYPERHAEMOLYSIS IN PATIENTS WITH HAEMOGLOBINOPATHIES | NHS ENGLAND |
ECULIZUMAB | NEUROMYELITIS OPTICA | NHS ENGLAND |
ECULIZUMAB | ORGAN REJECTION POST KIDNEY TRANSPLANT | NHS ENGLAND |
ECULIZUMAB | PAROXYSMAL NOCTURNAL HAEMOGLOBINURIA | NHS ENGLAND |
EFANESOCTOCOG ALFA | HAEMOPHILIA A | NHS ENGLAND |
EFAVIRENZ | HIV IN COMBINATION WITH OTHER ANTI-RETROVIRAL DRUGS | NHS ENGLAND |
EFGARTIGIMOD ALFA | MYASTHENIA GRAVIS | NHS ENGLAND |
EFMOROCTOCOG ALFA (EFRALOCTOCOG ALFA) (FACTOR VIII - recombinant) |
HAEMOPHILIA A | NHS ENGLAND |
EFRALOCTOCOG ALFA (see EFMOROCTOCOG ALFA) (FACTOR VIII - recombinant) |
HAEMOPHILIA A | NHS ENGLAND |
EFRENONACOG ALFA (see EFTRENONACOG ALFA) (FACTOR IX - recombinant) |
HAEMOPHILIA B | NHS ENGLAND |
EFTRENONACOG ALFA (EFRENONACOG ALFA) (FACTOR IX - recombinant) |
HAEMOPHILIA B | NHS ENGLAND |
ELACESTRANT | CANCER Breast cancer |
CDF |
ELADOCAGENE EXUPARVOVEC | AROMATIC L-AMINO ACID DECARBOXYLASE (AADC) DEFICIENCY | NHS ENGLAND |
ELAFIBRANOR | PRIMARY BILIARY CHOLANGITIS | IMF |
ELAFIBRANOR | PRIMARY BILIARY CHOLANGITIS | NHS ENGLAND |
ELBASVIR | HEPATITIS C | NHS ENGLAND |
ELEXACAFTOR + TEZACAFTOR + IVACAFTOR | CYSTIC FIBROSIS | NHS ENGLAND |
ELEXACAFTOR + TEZACAFTOR + IVACAFTOR | CYSTIC FIBROSIS | NHS ENGLAND |
ELIGLUSTAT | GAUCHER'S DISEASE | NHS ENGLAND |
ELOSULFASE ALFA | MUCOPOLYSACCHARIDOSIS TYPE 4A | NHS ENGLAND |
ELOTUZUMAB | CANCER MM |
NHS ENGLAND |
ELRANATAMAB | CANCER MM |
CDF |
Eltrombopag (Revolade®) | Thrombocytopenia purpura | ICB |
Eltrombopag (Revolade®) | Severe aplastic anaemia in adults | ICB |
ELVITEGRAVIR | HIV IN COMBINATION WITH OTHER ANTI-RETROVIRAL DRUGS | NHS ENGLAND |
ELVITEGRAVIR | HIV IN COMBINATION WITH OTHER ANTI-RETROVIRAL DRUGS | NHS ENGLAND |
ELVUCITABINE | HIV IN COMBINATION WITH OTHER ANTI-RETROVIRAL DRUGS | NHS ENGLAND |
EMICIZUMAB | HAEMOPHILIA A with Factor VIII inhibitors |
NHS ENGLAND |
EMICIZUMAB | HAEMOPHILIA A without Factor VIII inhibitors |
NHS ENGLAND |
EMIPLACEL | MUSCLE INJURY FOLLOWING ARTHROPLASTY | NHS ENGLAND |
EMIXUSTAT | STARGARDT'S DISEASE | NHS ENGLAND |
EMTRICITABINE | HIV IN COMBINATION WITH OTHER ANTI-RETROVIRAL DRUGS | NHS ENGLAND |
EMTRICITABINE | HIV IN COMBINATION WITH OTHER ANTI-RETROVIRAL DRUGS | NHS ENGLAND |
EMTRICITABINE | HIV IN COMBINATION WITH OTHER ANTI-RETROVIRAL DRUGS | NHS ENGLAND |
EMTRICITABINE | HIV IN COMBINATION WITH OTHER ANTI-RETROVIRAL DRUGS | NHS ENGLAND |
EMTRICITABINE | HIV IN COMBINATION WITH OTHER ANTI-RETROVIRAL DRUGS | NHS ENGLAND |
ENCORAFENIB | CANCER Colorectal cancer |
NHS ENGLAND |
ENCORAFENIB | CANCER Melanoma |
NHS ENGLAND |
ENFORTUMAB VEDOTIN | CANCER Urothelial cancer |
NHS ENGLAND |
ENFUVIRTIDE | HIV IN COMBINATION WITH OTHER ANTI-RETROVIRAL DRUGS | NHS ENGLAND |
ENTRECTINIB | CANCER Lung cancer |
NHS ENGLAND |
ENTRECTINIB | CANCER NTRK fusion positive solid tumours |
CDF |
ENZALUTAMIDE | CANCER Prostate cancer |
NHS ENGLAND |
ENZALUTAMIDE | CANCER Prostate cancer |
NHS ENGLAND |
ENZALUTAMIDE | CANCER Prostate cancer |
NHS ENGLAND |
ENZALUTAMIDE | CANCER Prostate cancer |
NHS ENGLAND |
EPCORITAMAB | CANCER B-cell lymphoma |
NHS ENGLAND |
EPLONTERSEN | AMYLOIDOSIS | NHS ENGLAND |
EPOETIN ALPHA, BETA, THETA AND ZETA | DIALYSIS-INDUCED ANAEMIA | NHS ENGLAND |
EPOPROSTENOL | DIGITAL ULCERS | NHS ENGLAND |
EPOPROSTENOL | PULMONARY ARTERIAL HYPERTENSION | NHS ENGLAND |
EPRATUZUMAB | SYSTEMIC LUPUS ERYTHEMATOSUS (SLE) | NHS ENGLAND |
EPRODISATE | AMYLOIDOSIS | NHS ENGLAND |
EPTACOG ALFA (ACTIVATED) (FACTOR VIIa - recombinant) |
AS PER BCSH GUIDELINES FOR SPECIALISED INDICATIONS | NHS ENGLAND |
EPTACOG BETA (ACTIVATED) (FACTOR VIIa - recombinant) |
AS PER BCSH GUIDELINES FOR SPECIALISED INDICATIONS | NHS ENGLAND |
Eptinezumab (Vyepti®) | Migraine | ICB |
Erenumab (Aimovig®) | Migraine | ICB |
ERIBULIN | CANCER Breast cancer |
NHS ENGLAND |
ERLOTINIB | CANCER Lung cancer |
NHS ENGLAND |
ERLOTINIB | CANCER Lung cancer |
NHS ENGLAND |
ERLOTINIB | CANCER Lung cancer |
NHS ENGLAND |
ETANERCEPT | JUVENILE IDIOPATHIC ARTHRITIS - PAEDIATRICS | NHS ENGLAND |
ETANERCEPT | JUVENILE IDIOPATHIC ARTHRITIS - PAEDIATRICS | NHS ENGLAND |
ETANERCEPT | BEHCETS SYNDROME | NHS ENGLAND |
ETANERCEPT | PLAQUE PSORIASIS - PAEDIATRICS | NHS ENGLAND |
Etanercept (Enbrel®, Erelzi®, Benepali®) | Ankylosing spondylitis | ICB |
Etanercept (Enbrel®, Erelzi®, Benepali®) | Psoriasis | ICB |
Etanercept (Enbrel®, Erelzi®, Benepali®) | Psoriatic Arthritis | ICB |
Etanercept (Enbrel®, Erelzi®, Benepali®) | Rheumatoid arthritis | ICB |
Etanercept (Enbrel®, Erelzi®, Benepali®) | Juvenile arthritis (adult) | ICB |
ETEPLIRSEN | DUCHENNE MUSCULAR DYSTROPHY | NHS ENGLAND |
ETRANACOGENE DEZAPARVOVEC | HAEMOPHILIA B | IMF |
ETRASIMOD | ULCERATIVE COLITIS - PAEDIATRICS | NHS ENGLAND |
Etrasimod (Velsipity®) | Ulcerative Colitis (moderate to severe) | ICB |
ETRAVIRINE | HIV IN COMBINATION WITH OTHER ANTI-RETROVIRAL DRUGS | NHS ENGLAND |
EVEROLIMUS | CANCER Breast cancer |
NHS ENGLAND |
EVEROLIMUS | CANCER NETs |
NHS ENGLAND |
EVEROLIMUS | CANCER Renal cell carcinoma |
NHS ENGLAND |
EVEROLIMUS | CANCER Renal cell carcinoma |
NHS ENGLAND |
EVEROLIMUS | KIDNEY TRANSPLANT - ADULTS | NHS ENGLAND |
EVEROLIMUS | KIDNEY TRANSPLANT - CHILDREN & YOUNG PEOPLE | NHS ENGLAND |
EVEROLIMUS | PREVENTING ORGAN REJECTION IN HEART TRANSPLANTATION | NHS ENGLAND |
EVEROLIMUS | PREVENTING ORGAN REJECTION IN LIVER TRANSPLANTATION | NHS ENGLAND |
EVEROLIMUS | RENAL ANGIOMYOLIPOMA ASSOCIATED WITH TUBEROUS SCLEROSIS | NHS ENGLAND |
EVEROLIMUS | SEIZURES ASSOCIATED WITH SUBEPENDYMAL GIANT CELL ASTROCYTOMA (SEGA) ASSOCIATED WITH TUBEROUS SCLEROSIS COMPLEX | NHS ENGLAND |
EVEROLIMUS | SUBEPENDYMAL GIANT CELL ASTROCYTOMA (SEGA) ASSOCIATED WITH TUBEROUS SCLEROSIS COMPLEX | NHS ENGLAND |
EVINACUMAB | HOMOZYGOUS FAMILIAL HYPERCHOLESTEROLAEMIA | NHS ENGLAND |
EVOLOCUMAB | HOMOZYGOUS FAMILIAL HYPERCHOLESTEROLAEMIA | NHS ENGLAND |
Evolocumab (Repatha SureClick®) | Primary hypercholesterolaemia or mixed dyslipidaemia | ICB |
Evolocumab (Repatha SureClick®) | Primary heterozygous-familial hypercholesterolaemia | ICB |
EXAGAMGLOGENE AUTOTEMCEL | SICKLE CELL DISEASE | NHS ENGLAND |
EXAGAMGLOGENE AUTOTEMCEL | THALASSAEMIA | IMF |
EX-VIVO EXPANDED AUTOLOGOUS HUMAN CORNEAL EPITHELIAL CELLS CONTAINING STEM CELLS | TREATMENT OF ADULT PATIENTS WITH MODERATE TO SEVERE LIMBAL STEM CELL DEFICIENCY (LSCD), UNILATERAL OR BILATERAL, DUE TO PHYSICAL OR CHEMICAL OCULAR BURNS | NHS ENGLAND |
FACTOR IX - see drug names | HAEMOPHILIA B | NHS ENGLAND |
FACTOR VII | AS PER BCSH GUIDELINES FOR SPECIALISED INDICATIONS | NHS ENGLAND |
FACTOR VIIa - see drug names | AS PER BCSH GUIDELINES FOR SPECIALISED INDICATIONS | NHS ENGLAND |
FACTOR VIII - see drug names | HAEMOPHILIA A | NHS ENGLAND |
FACTOR VIII + VON WILLEBRAND FACTOR (VON WILLEBRAND FACTOR - PLASMA with FVIII) |
VON WILLEBRAND DEFICIENCY | NHS ENGLAND |
FACTOR VIII INHIBITOR BYPASSING FRACTION | AS PER BCSH GUIDELINES FOR SPECIALISED INDICATIONS | NHS ENGLAND |
FACTOR X (see HUMAN COAGULATION FACTOR X) (FACTOR X - plasma derived) |
AS PER BCSH GUIDELINES FOR SPECIALISED INDICATIONS | NHS ENGLAND |
FACTOR XI | AS PER BCSH GUIDELINES FOR SPECIALISED INDICATIONS | NHS ENGLAND |
FACTOR XIII (FACTOR XIII - plasma derived) |
AS PER BCSH GUIDELINES FOR SPECIALISED INDICATIONS | NHS ENGLAND |
FAMPRIDINE | MULTIPLE SCLEROSIS | NHS ENGLAND |
Faricimab (Vabysmo®) | Macular oedema after RVO | ICB |
Faricimab (Vabysmo®) | Diabetic Macular Oedema | ICB |
Faricimab (Vabysmo®) | Macular degeneration(wet age-related) | ICB |
FEDRATINIB | CANCER Myelofibrosis |
CDF |
FEDRATINIB | CANCER Myelofibrosis |
NHS ENGLAND |
FENFLURAMINE | DRAVET SYNDROME | NHS ENGLAND |
FIBRINOGEN | AS PER BCSH GUIDELINES FOR SPECIALISED INDICATIONS | NHS ENGLAND |
FIDANACOGENE ELAPARVOVEC | HAEMOPHILIA B | NHS ENGLAND |
Fidaxomicin | Recurrent Clostridium Difficile Infection | ICB |
Filgotinib (Jyseleca®) | Ulcerative Colitis (moderate to severe) | ICB |
Filgotinib (Jyseleca®) | Moderate to Severe Rheumatoid Arthritis | ICB |
FINGOLIMOD | MULTIPLE SCLEROSIS | NHS ENGLAND |
FINGOLIMOD | MULTIPLE SCLEROSIS | NHS ENGLAND |
FITUSIRAN | HAEMOPHILIA A AND B | NHS ENGLAND |
Fluocinolone acetonide (Iluvien®) | Non-infections uveitis | ICB |
Fluocinolone acetonide (Iluvien®) | Diabetic Macular Oedema | ICB |
Fomepizole | Ethylene glycol poisoning and Methanol poisoning | ICB |
FORDADISTROGENE MOVAPARVOVEC | DUCHENNE MUSCULAR DYSTROPHY | NHS ENGLAND |
FORIGERIMOD ACETATE | SYSTEMIC LUPUS ERYTHEMATOSUS (SLE) | NHS ENGLAND |
FOSAMPRENAVIR | HIV IN COMBINATION WITH OTHER ANTI-RETROVIRAL DRUGS | NHS ENGLAND |
FOSDENOPTERIN (CYCLIC PYRANOPTERIN MONOPHOSPHATE) | MOLYBDENUM COFACTOR DEFICIENCY | NHS ENGLAND |
FOSLEVODOPA-FOSCARBIDOPA | PARKINSON'S DISEASE | NHS ENGLAND |
Fostamatinib (Tavlesse®) | Chronic immune thrombocytopenia | ICB |
FOSTEMSAVIR | HIV IN COMBINATION WITH OTHER ANTI-RETROVIRAL DRUGS | NHS ENGLAND |
Fremanezumab (Ajovy®) | Migraine | ICB |
FUTIBATINIB | CANCER Cholangiocarcinoma |
NHS ENGLAND |
Galcanezumab (Emgality®) | Migraine | ICB |
GALSULFASE | MUCOPOLYSACCHARIDOSIS | NHS ENGLAND |
GANAXOLONE | SEIIZURES ASSOCIATED WITH CYCLIN-DEPENDENT KINASE-LIKE 5 DEFICIENCY DISORDER | NHS ENGLAND |
GEFITINIB | CANCER Lung cancer |
NHS ENGLAND |
GEFITINIB | CANCER Lung cancer |
NHS ENGLAND |
GEMCITABINE | CANCER Biliary tract cancer |
NHS ENGLAND |
GEMCITABINE (WITH CAPECITABINE) | CANCER Pancreatic cancer |
NHS ENGLAND |
GEMTUZUMAB OZOGAMICIN | CANCER AML |
NHS ENGLAND |
GILTERITINIB | CANCER AML |
NHS ENGLAND |
GIROCTOCOGENE FITELPARVOVEC | HAEMOPHILIA A | NHS ENGLAND |
GIVOSIRAN | HEPATIC PORPHYRIA | NHS ENGLAND |
GLATIRAMER | MULTIPLE SCLEROSIS | NHS ENGLAND |
GLATIRAMER | MULTIPLE SCLEROSIS | NHS ENGLAND |
GLECAPREVIR | HEPATITIS C | NHS ENGLAND |
GLOFITAMAB | CANCER DLBCL |
NHS ENGLAND |
GLUCARPIDASE | METHOTREXATE INDUCED RENAL DYSFUNCTION | NHS ENGLAND |
GLYCEROL PHENYLBUTYRATE | UREA CYCLE DISORDERS | NHS ENGLAND |
Golimumab (Simponi®) | Ankylosing Spondylitis | ICB |
Golimumab (Simponi®) | Psoriatic arthritis | ICB |
Golimumab (Simponi®) | Rheumatoid arthritis | ICB |
Golimumab (Simponi®) | Ulcerative Colitis (moderate to severe) | ICB |
GRANULOCYTE-MACROPHAGE COLONY-STIMULATING FACTOR | ANTIBODY-POSITIVE PULMONARY ALVEOLAR PROTEINOSIS | NHS ENGLAND |
GRAZOPREVIR | HEPATITIS C | NHS ENGLAND |
Guselkumab (Tremfya ®) | Psoriatic arthritis | ICB |
Guselkumab (Tremfya ®) | Moderate to severe plaque psoriasis | ICB |
HAEM ARGINATE | HEPATIC PORPHYRIA | NHS ENGLAND |
HIGH PURITY FACTOR IX (FACTOR IX - plasma derived) |
HAEMOPHILIA B | NHS ENGLAND |
HIGH PURITY FACTOR VIII (FACTOR VIII - plasma derived) |
HAEMOPHILIA A | NHS ENGLAND |
HUMAN ALPHA1-PROTEINASE INHIBITOR | EMPHYSEMA | NHS ENGLAND |
HUMAN COAGULATION FACTOR X | FACTOR X DEFICIENCY | NHS ENGLAND |
HUMAN HETEROLOGOUS LIVER CELLS | UREA CYCLE DISORDERS | NHS ENGLAND |
HUMAN NORMAL IMMUNOGLOBULINS - INTRAVENOUS | MULTIPLE INDICATIONS | NHS ENGLAND |
HUMAN NORMAL IMMUNOGLOBULINS - INTRAVENOUS | SCLEROMYXEDEMA | NHS ENGLAND |
HUMAN NORMAL IMMUNOGLOBULINS - SUBCUTANEOUS | MULTIPLE INDICATIONS | NHS ENGLAND |
HUMAN NORMAL IMMUNOGLOBULINS - SUBCUTANEOUS | SCLEROMYXEDEMA | NHS ENGLAND |
HUMAN PARATHYROID HORMONE-RELATED PROTEIN ANALOGUE | MALE AND JUVENILE OSTEOPOROSIS HYPOPARATHYROIDISM |
NHS ENGLAND |
HYDROXYPROPYL BETADEX | NHS ENGLAND | |
IBALIZUMAB | HIV IN COMBINATION WITH OTHER ANTI-RETROVIRAL DRUGS | NHS ENGLAND |
IBRUTINIB | CANCER CLL |
NHS ENGLAND |
IBRUTINIB | CANCER CLL |
NHS ENGLAND |
IBRUTINIB | CANCER CLL |
NHS ENGLAND |
IBRUTINIB | CANCER CLL |
NHS ENGLAND |
IBRUTINIB | CANCER CLL |
NHS ENGLAND |
IBRUTINIB | CANCER CLL |
NHS ENGLAND |
IBRUTINIB | CANCER MCL |
NHS ENGLAND |
IBRUTINIB | CANCER Waldenstrom's macroglobulinaemia |
NHS ENGLAND |
IBRUTINIB | CANCER Waldenstrom's macroglobulinaemia |
NHS ENGLAND |
ICATIBANT | HEREDITARY ANGIOEDEMA - ACUTE TREATMENT ONLY | NHS ENGLAND |
ICATIBANT | HEREDITARY ANGIOEDEMA - ACUTE TREATMENT ONLY | NHS ENGLAND |
IDEBENONE | DUCHENNE MUSCULAR DYSTROPHY | NHS ENGLAND |
IDEBENONE | LEBER HEREDITARY OPTIC NEUROPATHY | NHS ENGLAND |
IDECABTAGENE VICLEUCEL | CANCER MM |
NHS ENGLAND |
IDELALISIB | CANCER CLL |
NHS ENGLAND |
IDURSULFASE | MUCOPOLYSACCHARIDOSIS | NHS ENGLAND |
ILOPROST | DIGITAL ULCERS | NHS ENGLAND |
ILOPROST | PULMONARY ARTERIAL HYPERTENSION | NHS ENGLAND |
IMATINIB | CANCER CML |
NHS ENGLAND |
IMATINIB | CANCER CML |
NHS ENGLAND |
IMATINIB | CANCER CML |
NHS ENGLAND |
IMATINIB | CANCER Gastrointestinal stromal tumour |
NHS ENGLAND |
IMATINIB | CANCER Gastrointestinal stromal tumour |
NHS ENGLAND |
IMATINIB | CANCER Gastrointestinal stromal tumour |
NHS ENGLAND |
IMATINIB | CHRONIC GRAFT VERSUS HOST DISEASE | NHS ENGLAND |
IMETELSTAT | CANCER | NHS ENGLAND |
IMIGLUCERASE | GAUCHER'S DISEASE | NHS ENGLAND |
IMLIFIDASE | TRANSPLANT REJECTION PREVENTION IN HLA-SENSITISED PATIENTS | NHS ENGLAND |
INCLISIRAN | PRIMARY HYPERCHOLESTEROLAEMIA OR MIXED DYSLIPIDAEMIA | NHS ENGLAND |
INCLISIRAN | PRIMARY HYPERCHOLESTEROLAEMIA OR MIXED DYSLIPIDAEMIA | NHS ENGLAND |
INDINAVIR | HIV IN COMBINATION WITH OTHER ANTI-RETROVIRAL DRUGS | NHS ENGLAND |
INEBILIZUMAB | MULTIPLE SCLEROSIS | NHS ENGLAND |
INFLIXIMAB | BEHCETS SYNDROME | NHS ENGLAND |
INFLIXIMAB | CONNECTIVE TISSUE DISEASE - INTERSTITAL LUNG DISEASE | NHS ENGLAND |
INFLIXIMAB | CROHN'S DISEASE - PAEDIATRICS | NHS ENGLAND |
INFLIXIMAB | GRAFT VERSUS HOST DISEASE | NHS ENGLAND |
INFLIXIMAB | HIDRADENITIS SUPPURATIVA | NHS ENGLAND |
INFLIXIMAB | JUVENILE IDIOPATHIC ARTHRITIS - PAEDIATRICS | NHS ENGLAND |
INFLIXIMAB | PULMONARY SARCOIDOSIS | NHS ENGLAND |
INFLIXIMAB | REFRACTORY SARCOIDOSIS | NHS ENGLAND |
INFLIXIMAB | REFRACTORY OR PROGRESSIVE NEUROSARCOIDOSIS | NHS ENGLAND |
INFLIXIMAB | ULCERATIVE COLITIS - PAEDIATRICS | NHS ENGLAND |
INFLIXIMAB | UVEITIS | NHS ENGLAND |
Infliximab (Inflectra, Remsima, Remicade®) | Ankylosing spondylitis | ICB |
Infliximab (Inflectra, Remsima, Remicade®) | Crohn’s disease | ICB |
Infliximab (Inflectra, Remsima, Remicade®) | Psoriasis | ICB |
Infliximab (Inflectra, Remsima, Remicade®) | Psoriatic Arthritis | ICB |
Infliximab (Inflectra, Remsima, Remicade®) | Rheumatoid arthritis | ICB |
Infliximab (Inflectra, Remsima, Remicade®) | Diarrhoea and colitis relating to ICPI therapy | ICB |
Infliximab (Inflectra, Remsima, Remicade®) | Ulcerative Colitis (moderate to severe) | ICB |
INOTERSEN | AMYLOIDOSIS | NHS ENGLAND |
INOTUZUMAB OZOGAMICIN | CANCER ALL |
NHS ENGLAND |
INTERFERON ALFA (Pegylated and non-pegylated) | HEPATITIS B AND C | NHS ENGLAND |
INTERFERON ALFA N3 | MIDDLE EAST RESPIRATORY SYNDROME | NHS ENGLAND |
INTERFERON BETA | MULTIPLE SCLEROSIS | NHS ENGLAND |
INTERFERON BETA | MULTIPLE SCLEROSIS | NHS ENGLAND |
INTERFERON BETA | MULTIPLE SCLEROSIS | NHS ENGLAND |
INVERTASE | NHS ENGLAND | |
INVIMESTROCEL | STROKE | NHS ENGLAND |
IPILIMUMAB | CANCER Lung cancer |
NHS ENGLAND |
IPILIMUMAB | CANCER Melanoma |
NHS ENGLAND |
IPILIMUMAB | CANCER Melanoma |
NHS ENGLAND |
IPILIMUMAB | CANCER Melanoma |
NHS ENGLAND |
IPILIMUMAB | CANCER Mesothelioma |
NHS ENGLAND |
IPILIMUMAB | CANCER Renal cell carcinoma |
NHS ENGLAND |
IPILIMUMAB | CANCER Colorectal cancer |
NHS ENGLAND |
IPTACOPAN | PAROXYSMAL NOCTURNAL HAEMOGLOBINURIA | NHS ENGLAND |
ISATUXIMAB | CANCER MM |
CDF |
ISATUXIMAB | CANCER MM |
CDF |
ISAVUCONAZOLE | FUNGAL INFECTION (LICENSED INDICATIONS) | NHS ENGLAND |
IVACAFTOR | CYSTIC FIBROSIS | NHS ENGLAND |
IVOSIDENIB | CANCER Cholangiocarcinoma |
NHS ENGLAND |
IVOSIDENIB | CANCER AML |
NHS ENGLAND |
IXAZOMIB | AMYLOIDOSIS | NHS ENGLAND |
IXAZOMIB | CANCER MM |
NHS ENGLAND |
Ixekizumab (Taltz®) | Moderate to severe plaque psoriasis | ICB |
Ixekizumab (Taltz®) | Axial spondyloarthritis | ICB |
Ixekizumab (Taltz®) | Psoriatic Arthritis | ICB |
LANADELUMAB | HEREDITARY ANGIOEDEMA - PROPHYLACTIC TREATMENT | NHS ENGLAND |
LANREOTIDE | ACROMEGALY | NHS ENGLAND |
LANREOTIDE | CANCER | NHS ENGLAND |
LANREOTIDE | CONGENITAL HYPERINSULINISM | NHS ENGLAND |
LAPATINIB | CANCER Breast cancer |
NHS ENGLAND |
L-ARGININE | UREA CYCLE DISORDERS | NHS ENGLAND |
LARONIDASE | MUCOPOLYSACCHARIDOSIS | NHS ENGLAND |
LAROTRECTINIB | CANCER NTRK fusion positive solid tumours |
CDF |
LEBRIKIZUMAB | ASTHMA | NHS ENGLAND |
LEBRIKIZUMAB | MODERATE TO SEVERE ATOPIC DERMATITIS - PAEDIATRICS | NHS ENGLAND |
Lebrikizumab (Ebglyss®) | Moderate to severe atopic dermatitis | ICB |
LENABASUM (ANABASUM) | SCLERODERMA | NHS ENGLAND |
LENACAPAVIR | HIV IN COMBINATION WITH OTHER ANTI-RETROVIRAL DRUGS | NHS ENGLAND |
LENADOGENE NOLPARVOVEC | LEBER HEREDITARY OPTIC NEUROPATHY | NHS ENGLAND |
LENALIDOMIDE | CANCER Follicular lymphoma |
NHS ENGLAND |
LENALIDOMIDE | CANCER MDS |
NHS ENGLAND |
LENALIDOMIDE | CANCER MM |
NHS ENGLAND |
LENALIDOMIDE | CANCER MM |
NHS ENGLAND |
LENALIDOMIDE | CANCER MM |
NHS ENGLAND |
LENALIDOMIDE | CANCER MM |
NHS ENGLAND |
LENALIDOMIDE | CANCER MM |
NHS ENGLAND |
LENALIDOMIDE | CANCER MM |
NHS ENGLAND |
LENALIDOMIDE | CANCER MM |
CDF |
LENALIDOMIDE | POEMS | NHS ENGLAND |
LENIOLISIB | PHOSPHOINOSITIDE 3-KINASE DELTA SYNDROME | NHS ENGLAND |
LENVATINIB | CANCER Endometrial cancer |
NHS ENGLAND |
LENVATINIB | CANCER Hepatocellular carcinoma |
NHS ENGLAND |
LENVATINIB | CANCER Renal cell carcinoma |
NHS ENGLAND |
LENVATINIB | CANCER Renal cell carcinoma |
NHS ENGLAND |
LENVATINIB | CANCER Thyroid cancer |
NHS ENGLAND |
LERIGLITAZONE | ADRENOMYELONEUROPTHY (AMN) IN MALE ADULTS | NHS ENGLAND |
LERONLIMAB | HIV IN COMBINATION WITH OTHER ANTI-RETROVIRAL DRUGS | NHS ENGLAND |
LETERMOVIR | CYTOMEGALOVIRUS | NHS ENGLAND |
LETETRESGENE AUTOLEUCEL | CANCER Sarcoma |
NHS ENGLAND |
LEVODOPA + CARBIDOPA + ENTACAPONE (INTESTINAL GEL) | PARKINSON'S DISEASE | NHS ENGLAND |
LEVODOPA + CARBIDOPA INTESTINAL GEL | PARKINSON'S DISEASE | NHS ENGLAND |
LEVOFLOXACIN (INHALED) | CYSTIC FIBROSIS | NHS ENGLAND |
LEVOKETOCONAZOLE | CUSHING'S DISEASE | NHS ENGLAND |
LIFILEUCEL | CANCER | NHS ENGLAND |
Liothyronine | Myxoedema coma | ICB |
LIPOSOMAL CYTARABINE-DAUNORUBICIN | CANCER AML |
NHS ENGLAND |
LISOCABTAGENE MARALEUCEL | CANCER NHL |
NHS ENGLAND |
LOMITAPIDE | HOMOZYGOUS FAMILIAL HYPERCHOLESTEROLAEMIA | NHS ENGLAND |
LONAFARNIB | PROGERIA AND PROGEROID LAMINOPATHIES | NHS ENGLAND |
LONCASTUXIMAB | CANCER B-cell lymphoma |
NHS ENGLAND |
LONOCTOCOG ALFA (FACTOR VIII - recombinant) |
HAEMOPHILIA A | NHS ENGLAND |
LOPINAVIR | HIV IN COMBINATION WITH OTHER ANTI-RETROVIRAL DRUGS | NHS ENGLAND |
LORLATINIB | CANCER Lung cancer |
NHS ENGLAND |
LORLATINIB | CANCER Lung cancer |
NHS ENGLAND |
LUMACAFTOR + IVACAFTOR | CYSTIC FIBROSIS | NHS ENGLAND |
LUMACAFTOR + IVACAFTOR | CYSTIC FIBROSIS | NHS ENGLAND |
LUMASIRAN | PRIMARY HYPEROXALURIA | NHS ENGLAND |
LUSPATERCEPT | CANCER | NHS ENGLAND |
Lusutrombopag (Mulpleo ®) | Thrombocytopenia in people with chronic liver disease | ICB |
LUTETIUM (177Lu) OXODOTREOTIDE | CANCER NET |
NHS ENGLAND |
LUTETIUM (177Lu) VIPIVOTIDE TETRAXETAN | CANCER Prostate cancer |
NHS ENGLAND |
MACITENTAN | PULMONARY ARTERIAL HYPERTENSION | NHS ENGLAND |
MANNITOL (INHALED) | CYSTIC FIBROSIS | NHS ENGLAND |
MANNITOL (INHALED) | CYSTIC FIBROSIS | NHS ENGLAND |
MARALIXIBAT | ALAGILLE SYNDROME | NHS ENGLAND |
MARAVIROC | HIV IN COMBINATION WITH OTHER ANTI-RETROVIRAL DRUGS | NHS ENGLAND |
MARAVIROC | NATALIZUMAB INDUCED PML | NHS ENGLAND |
MARIBAVIR | CYTOMEGALOVIRUS | NHS ENGLAND |
MARNETEGRAGENE AUTOTEMCEL | LEUKOCYTE ADHESION DEFICIENCY-1 | NHS ENGLAND |
MARSTACIMAB | HAEMOPHILIA A AND B | NHS ENGLAND |
MASITINIB | CANCER | NHS ENGLAND |
MAVACAMTEN | SYMPTOMATIC HYPERTROPHIC CARDIOMYOPATHY | NHS ENGLAND |
MECASERMIN | GROWTH FAILURE | NHS ENGLAND |
MEPOLIZUMAB | ASTHMA, EOSINOPHILIC ASTHMA | NHS ENGLAND |
MERCAPTAMINE HCL VISCOUS EYEDROPS | CORNEAL CYSTINE DEPOSITS | NHS ENGLAND |
MESENCHYMAL STEM CELLS | ACUTE GVHD AND OTHER INDICATIONS (BCSH) | NHS ENGLAND |
METRELEPTIN | CONGENITAL LEPTIN DEFICIENCY | NHS ENGLAND |
METRELEPTIN | DYSLIPIDAEMIA | NHS ENGLAND |
METRELEPTIN | LIPODYSTROPHY | NHS ENGLAND |
MEXILETINE | NON-DYSTROPHIC MYOTONIC DISORDERS | NHS ENGLAND |
MICAFUNGIN | FUNGAL INFECTION | NHS ENGLAND |
MIDOSTAURIN | CANCER AML |
NHS ENGLAND |
MIDOSTAURIN | CANCER Mastocytosis |
NHS ENGLAND |
MIFAMURTIDE | CANCER Osteosarcoma |
NHS ENGLAND |
MIGALASTAT | FABRY'S DISEASE | NHS ENGLAND |
MIGLUSTAT | GLYCOGEN STORAGE DISEASE TYPE II (POMPE DISEASE) | NHS ENGLAND |
MIGLUSTAT | GAUCHER'S DISEASE/ NIEMANN-PICK | NHS ENGLAND |
Mirikizumab (Omvoh®) | Ulcerative Colitis (moderate to severe) | ICB |
MITAPIVAT | PYRUVATE KINASE DEFICIENCY | NHS ENGLAND |
MOBOCERTINIB | CANCER Lung cancer |
NHS ENGLAND |
MOGAMULIZUMAB | MYCOSIS FUNGOIDES | NHS ENGLAND |
MOMELOTINIB | CANCER Myelofibrosis-related splenomegaly or symptoms |
NHS ENGLAND |
MOROCTOCOG ALFA (FACTOR VIII - recombinant) |
HAEMOPHILIA A | NHS ENGLAND |
MOSUNETUZUMAB | CANCER Follicular lymphoma |
NHS ENGLAND |
MOZAFANCOGENE AUTOTEMCEL | FANCONI ANAEMA | NHS ENGLAND |
MYCOPHENOLATE MOFETIL | KIDNEY TRANSPLANT - ADULTS | NHS ENGLAND |
MYCOPHENOLATE MOFETIL | KIDNEY TRANSPLANT - CHILDREN & YOUNG PEOPLE | NHS ENGLAND |
MYCOPHENOLATE MOFETIL | TRANSPLANT IMMUNOSUPPRESSION ONLY - ADULTS | NHS ENGLAND |
MYCOPHENOLATE MOFETIL | TRANSPLANT IMMUNOSUPPRESSION ONLY - CHILDREN & YOUNG PEOPLE | NHS ENGLAND |
MYCOPHENOLIC ACID (sodium salt) | KIDNEY TRANSPLANT - ADULTS | NHS ENGLAND |
MYCOPHENOLIC ACID (sodium salt) | KIDNEY TRANSPLANT - CHILDREN & YOUNG PEOPLE | NHS ENGLAND |
MYCOPHENOLIC ACID (sodium salt) | TRANSPLANT IMMUNOSUPPRESSION ONLY - ADULTS | NHS ENGLAND |
MYCOPHENOLIC ACID (sodium salt) | TRANSPLANT IMMUNOSUPPRESSION ONLY - CHILDREN & YOUNG PEOPLE | NHS ENGLAND |
NAB-PACLITAXEL - ALBUMIN BOUND PACLITAXEL (WITH ATEZOLIZUMAB) | CANCER Breast cancer |
NHS ENGLAND |
NAB-PACLITAXEL - ALBUMIN BOUND PACLITAXEL (WITH GEMCITABINE) | CANCER Pancreatic cancer |
NHS ENGLAND |
NADOFARANGENE FIRADENOVEC | CANCER Bladder |
NHS ENGLAND |
NARSOPLIMAB | HAEMATOPOIETIC STEM CELL TRANSPLANT-RELATED THROMBOTIC MICROANGIOPATHY (HSCT-TMA) | NHS ENGLAND |
NATALIZUMAB | MULTIPLE SCLEROSIS | NHS ENGLAND |
NATALIZUMAB | MULTIPLE SCLEROSIS | NHS ENGLAND |
NAVITOCLAX | MYELOFIBROSIS | NHS ENGLAND |
NECITUMUMAB | CANCER Lung cancer |
NHS ENGLAND |
NEDOSIRAN | HYPEROXALURIA | NHS ENGLAND |
NELARABINE | CANCER ALL/NHL |
NHS ENGLAND CDF |
NELFINAVIR | HIV IN COMBINATION WITH OTHER ANTI-RETROVIRAL DRUGS | NHS ENGLAND |
NERATINIB | CANCER Breast cancer |
NHS ENGLAND |
NEVIRAPINE | HIV IN COMBINATION WITH OTHER ANTI-RETROVIRAL DRUGS | NHS ENGLAND |
NEXOBRID (BROMELAIN) | NHS ENGLAND | |
NICARDIPINE - INTRACRANIAL IMPLANT | SUBARACHNOID HAEMORRHAGE | NHS ENGLAND |
NILOTINIB | CANCER CML |
NHS ENGLAND |
NILOTINIB | CANCER CML |
NHS ENGLAND |
NINTEDANIB | CANCER Lung cancer |
NHS ENGLAND |
NINTEDANIB | IDIOPATHIC PULMONARY FIBROSIS | NHS ENGLAND |
NINTEDANIB | IDIOPATHIC PULMONARY FIBROSIS | NHS ENGLAND |
NINTEDANIB | PROGESSIVE FIBROSING INTERSTITIAL LUNG DISEASES | NHS ENGLAND |
NIRAPARIB | CANCER Ovarian, fallopian tube and peritoneal cancer |
NHS ENGLAND |
NIRAPARIB | CANCER Ovarian, fallopian tube and peritoneal cancer |
CDF |
Nirmatrelvir plus ritonavir (Paxlovid®) | Covid-19 | ICB |
NIRSEVIMAB | RSV PROPHYLAXIS | NHS ENGLAND |
NITAZOXANIDE | HEPATITIS C | NHS ENGLAND |
NITISINONE | ALKAPTONURIA | NHS ENGLAND |
NITISINONE | TYROSINAEMIA | NHS ENGLAND |
NITRIC OXIDE | PULMONARY ARTERIAL HYPERTENSION | NHS ENGLAND |
NIVOLUMAB | CANCER Colorectal cancer |
NHS ENGLAND |
NIVOLUMAB | CANCER Gastric, gastro-oesophageal or oesophageal carcinoma |
NHS ENGLAND |
NIVOLUMAB | CANCER Head and neck cancer |
NHS ENGLAND |
NIVOLUMAB | CANCER Hodgkin lymphoma |
NHS ENGLAND |
NIVOLUMAB | CANCER Lung cancer |
NHS ENGLAND |
NIVOLUMAB | CANCER Lung cancer |
NHS ENGLAND |
NIVOLUMAB | CANCER Lung cancer |
NHS ENGLAND |
NIVOLUMAB | CANCER Lung cancer |
NHS ENGLAND |
NIVOLUMAB | CANCER Melanoma |
NHS ENGLAND |
NIVOLUMAB | CANCER Melanoma |
NHS ENGLAND |
NIVOLUMAB | CANCER Melanoma |
NHS ENGLAND |
NIVOLUMAB | CANCER Melanoma |
NHS ENGLAND |
NIVOLUMAB | CANCER Mesothelioma |
NHS ENGLAND |
NIVOLUMAB | CANCER Oesophageal cancer |
NHS ENGLAND |
NIVOLUMAB | CANCER Oesophageal carcinoma |
NHS ENGLAND |
NIVOLUMAB | CANCER Oesophageal carcinoma |
NHS ENGLAND |
NIVOLUMAB | CANCER Renal cell carcinoma |
NHS ENGLAND |
NIVOLUMAB | CANCER Renal cell carcinoma |
NHS ENGLAND |
NIVOLUMAB | CANCER Renal cell carcinoma |
NHS ENGLAND |
NIVOLUMAB | CANCER Urothelial cancer |
NHS ENGLAND |
NIVOLUMAB | CANCER Urothelial carcinoma |
NHS ENGLAND |
NONACOG ALFA (FACTOR IX - recombinant) |
HAEMOPHILIA B | NHS ENGLAND |
NONACOG BETA PEGOL (FACTOR IX - recombinant) |
HAEMOPHILIA B | NHS ENGLAND |
NONACOG GAMMA (FACTOR IX - recombinant) |
HAEMOPHILIA B | NHS ENGLAND |
NUSINERSEN | SPINAL MUSCULAR ATROPHY | NHS ENGLAND |
OBECABTAGENE AUTOLEUCEL | CANCER ALL |
NHS ENGLAND |
OBETICHOLIC ACID | PRIMARY BILIARY CHOLANGITIS | NHS ENGLAND |
OBILTOXAXIMAB | ANTHRAX | NHS ENGLAND |
OBINUTUZUMAB | CANCER DLBCL |
NHS ENGLAND |
OBINUTUZUMAB | CANCER CLL |
NHS ENGLAND |
OBINUTUZUMAB | CANCER CLL |
NHS ENGLAND |
OBINUTUZUMAB | CANCER Follicular lymphoma |
NHS ENGLAND |
OBINUTUZUMAB | CANCER Follicular lymphoma |
NHS ENGLAND |
OBINUTUZUMAB | THROMBOTIC THROMBOCYTOPENIC PURPURA | NHS ENGLAND |
OBINUTUZUMAB | SYSTEMIC LUPUS ERYTHEMATOSUS (SLE) | NHS ENGLAND |
OCRELIZUMAB | MULTIPLE SCLEROSIS | NHS ENGLAND |
OCRELIZUMAB | MULTIPLE SCLEROSIS | NHS ENGLAND |
Ocriplasmin (Jetrea®) | Retinal disorders- Vitreomacular traction | ICB |
OCTOCOG ALFA (FACTOR VIII - recombinant) |
HAEMOPHILIA A | NHS ENGLAND |
OCTREOLIN | ACROMEGALY | NHS ENGLAND |
OCTREOTIDE | ACROMEGALY | NHS ENGLAND |
OCTREOTIDE | CANCER | NHS ENGLAND |
OCTREOTIDE | CONGENITAL HYPERINSULINISM | NHS ENGLAND |
ODEVIXIBAT | PROGRESSIVE FAMILIAL INTRAHEPATIC CHOLESTASIS | NHS ENGLAND |
OFATUMUMAB | MULTIPLE SCLEROSIS | NHS ENGLAND |
OLAPARIB | CANCER Breast cancer |
NHS ENGLAND |
OLAPARIB | CANCER Prostate cancer |
NHS ENGLAND |
OLAPARIB | CANCER Prostate cancer |
NHS ENGLAND |
OLAPARIB | CANCER Breast cancer |
NHS ENGLAND |
OLAPARIB | CANCER Ovarian, fallopian tube and peritoneal cancer |
NHS ENGLAND |
OLAPARIB | CANCER Ovarian, fallopian tube and peritoneal cancer |
NHS ENGLAND |
OLAPARIB | CANCER Ovarian, fallopian tube and peritoneal cancer |
NHS ENGLAND |
OLAPARIB | CANCER Pancreatic cancer |
NHS ENGLAND |
OLAPARIB | CANCER Prostate cancer |
NHS ENGLAND |
OLENASUFLIGENE RELDUPARVOVEC | MUCOPOLYSACCHARIDOSIS | NHS ENGLAND |
OLIPUDASE ALFA | ACID SPHINGOMYELINASE DEFICIENCY | NHS ENGLAND |
OMALIZUMAB | ASTHMA | NHS ENGLAND |
Omalizumab (Xolair®) | Severe Chronic Spontaneous Urticaria | ICB |
OMBITASVIR + PARITAPREVIR+ RITONAVIR + DASABUVIR + RIBAVIRIN | HEPATITIS C | NHS ENGLAND |
ONASEMNOGENE ABEPARVOVEC | SPINAL MUSCULAR ATROPHY | NHS ENGLAND |
ONASEMNOGENE ABEPARVOVEC | SPINAL MUSCULAR ATROPHY | NHS ENGLAND |
OSILODROSTAT | CUSHING'S DISEASE | NHS ENGLAND |
OSIMERTINIB | CANCER Lung cancer |
NHS ENGLAND |
OSIMERTINIB | CANCER Lung cancer |
NHS ENGLAND |
OSIMERTINIB | CANCER Lung cancer |
CDF |
OSTEOCHONDRAL ALLOGRAFT | OSTEOCHONDRAL LESIONS KNEE | NHS ENGLAND |
OZANIMOD | MULTIPLE SCLEROSIS | NHS ENGLAND |
Ozanimod (Zeposia®) | Moderately to severe ulceratve colitis | ICB |
PACRITINIB | MYELOFIBROSIS | NHS ENGLAND |
PALBOCICLIB | CANCER Breast cancer |
NHS ENGLAND |
PALBOCICLIB | CANCER Breast cancer |
NHS ENGLAND |
PALIVIZUMAB | RSV PROPHYLAXIS | NHS ENGLAND |
PALOPEGTERIPARATIDE | HYPOPARATHYROIDISM | NHS ENGLAND |
PALOVAROTENE | FYBRODYSPLASIA OSSIFICANS PROGRESSIVA | NHS ENGLAND |
PANITUMUMAB | CANCER Colorectal cancer |
NHS ENGLAND |
PANITUMUMAB | CANCER Colorectal cancer |
NHS ENGLAND |
PANOBINOSTAT | CANCER MM |
NHS ENGLAND |
PARA-AMINOSALICYLIC ACID | MULTI DRUG RESISTANT TB | NHS ENGLAND |
PARATHYROID HORMONE | SPECIALIST ENDOCRINOLOGY CONDITIONS | NHS ENGLAND |
Parathyroid Hormone (Preotact®) | Osteoporosis | ICB |
PARENTERAL NUTRITION (HOME USE) | INTESTINAL FAILURE | NHS ENGLAND |
PARENTERAL NUTRITION (HOME USE) | INTESTINAL FAILURE | NHS ENGLAND |
PARENTERAL NUTRITION (INPATIENT USE) | INTESTINAL FAILURE; INADEQUATE/ UNSAFE ENTERAL FEEDING | NHS ENGLAND |
PARENTERAL NUTRITION (INPATIENT USE) | INTESTINAL FAILURE; INADEQUATE/ UNSAFE ENTERAL FEEDING | NHS ENGLAND |
PARENTERAL NUTRITION (INPATIENT USE) | INTESTINAL FAILURE; INADEQUATE/ UNSAFE ENTERAL FEEDING | NHS ENGLAND |
PARICALCITOL | HYPERPARATHYROIDISM | NHS ENGLAND |
PARICALCITOL | HYPERPARATHYROIDISM | NHS ENGLAND |
PARITAPREVIR | HEPATITIS C | NHS ENGLAND |
PASIREOTIDE | ACROMEGALY | NHS ENGLAND |
PASIREOTIDE DIASPARTATE | CUSHING'S DISEASE | NHS ENGLAND |
PATISIRAN | AMYLOIDOSIS | NHS ENGLAND |
PAZOPANIB | CANCER Granular cell tumour |
NHS ENGLAND |
PAZOPANIB | CANCER Renal cell carcinoma |
NHS ENGLAND |
PEGASPARGASE | CANCER ALL |
NHS ENGLAND |
PEGBELFERMIN | ALCOHOLIC FATTY LIVER DISEASE | NHS ENGLAND |
PEGCETACOPLAN | PAROXYSMAL NOCTURNAL HAEMOGLOBINURIA | NHS ENGLAND |
PEGINTERFERON ALFA-2A | HEPATITIS B | NHS ENGLAND |
PEGINTERFERON ALFA-2A | HEPATITIS B | NHS ENGLAND |
PEGINTERFERON ALFA-2A | HEPATITIS C | NHS ENGLAND |
PEGINTERFERON ALFA-2A | HEPATITIS C | NHS ENGLAND |
PEGINTERFERON ALFA-2A | HEPATITIS C | NHS ENGLAND |
PEGINTERFERON ALFA-2A | HEPATITIS C | NHS ENGLAND |
PEGINTERFERON ALFA-2A | HEPATITIS C | NHS ENGLAND |
PEGINTERFERON ALFA-2A | MYELOPROLIFERATIVE NEOPLASMS | NHS ENGLAND |
PEGINTERFERON BETA-1A | MULTIPLE SCLEROSIS | NHS ENGLAND |
PEGINTERFERON BETA-1A | MULTIPLE SCLEROSIS | NHS ENGLAND |
PEGUNIGALSIDASE ALFA | FABRY'S DISEASE | NHS ENGLAND |
PEGVALIASE | PHENYLKETONURIA | NHS ENGLAND |
PEGVISOMANT | ACROMEGALY | NHS ENGLAND |
PEGYLATED LIPOSOMAL DOXORUBICIN | CANCER Ovarian cancer |
NHS ENGLAND |
PEGYLATED LIPOSOMAL DOXORUBICIN | CANCER Sarcoma / Kaposi Sarcoma |
NHS ENGLAND |
PEMBROLIZUMAB | CANCER Endometrial, biliary, colorectal, gastric or small intestine cancer |
NHS ENGLAND |
PEMBROLIZUMAB | CANCER Breast cancer |
NHS ENGLAND |
PEMBROLIZUMAB | CANCER Breast cancer |
NHS ENGLAND |
PEMBROLIZUMAB | CANCER Colorectal cancer |
NHS ENGLAND |
PEMBROLIZUMAB | CANCER Endometrial cancer |
NHS ENGLAND |
PEMBROLIZUMAB | CANCER Head and neck cancer |
NHS ENGLAND |
PEMBROLIZUMAB | CANCER Hodgkin lymphoma |
NHS ENGLAND |
PEMBROLIZUMAB | CANCER Hodgkin lymphoma |
CDF |
PEMBROLIZUMAB | CANCER Hodgkin lymphoma |
NHS ENGLAND |
PEMBROLIZUMAB | CANCER Lung cancer |
NHS ENGLAND |
PEMBROLIZUMAB | CANCER Lung cancer |
NHS ENGLAND |
PEMBROLIZUMAB | CANCER Lung cancer |
NHS ENGLAND |
PEMBROLIZUMAB | CANCER Lung cancer |
NHS ENGLAND |
PEMBROLIZUMAB | CANCER Lung cancer |
CDF |
PEMBROLIZUMAB | CANCER Lung cancer |
NHS ENGLAND |
PEMBROLIZUMAB | CANCER Lung cancer |
CDF |
PEMBROLIZUMAB | CANCER Melanoma |
NHS ENGLAND |
PEMBROLIZUMAB | CANCER Melanoma |
NHS ENGLAND |
PEMBROLIZUMAB | CANCER Melanoma |
NHS ENGLAND |
PEMBROLIZUMAB | CANCER Melanoma |
NHS ENGLAND |
PEMBROLIZUMAB | CANCER Gastric/ gastro-oesophageal junction cancer |
NHS ENGLAND |
PEMBROLIZUMAB | CANCER Oesophageal/gastro-oesophageal junction cancer |
NHS ENGLAND |
PEMBROLIZUMAB | CANCER Renal cell carcinoma |
NHS ENGLAND |
PEMBROLIZUMAB | CANCER Renal cell carcinoma |
NHS ENGLAND |
PEMBROLIZUMAB | CANCER Renal cell carcinoma |
NHS ENGLAND |
PEMBROLIZUMAB | CANCER Urothelial carcinoma |
NHS ENGLAND |
PEMBROLIZUMAB | DRUG RESISTANT GESTATIONAL TROPHOBLASTIC NEOPLASIA | NHS ENGLAND |
PEMBROLIZUMAB | CANCER Cervical cancer |
NHS ENGLAND |
PEMETREXED | CANCER Lung cancer |
NHS ENGLAND |
PEMETREXED | CANCER Lung cancer |
NHS ENGLAND |
PEMETREXED | CANCER Lung cancer |
NHS ENGLAND |
PEMETREXED | CANCER Lung cancer |
NHS ENGLAND |
PEMETREXED | CANCER Lung cancer |
NHS ENGLAND |
PEMETREXED | CANCER Mesothelioma |
NHS ENGLAND |
PEMIGATINIB | CANCER Cholangiocarcinoma |
NHS ENGLAND |
PEPTIDE RECEPTOR RADIONUCLEOTIDE THERAPY | CANCER | CDF |
PERTUZUMAB | CANCER Breast cancer |
NHS ENGLAND |
PERTUZUMAB | CANCER Breast cancer |
NHS ENGLAND |
PERTUZUMAB | CANCER Breast cancer |
NHS ENGLAND |
PIBRENTASVIR | HEPATITIS C | NHS ENGLAND |
PIRFENIDONE | IDIOPATHIC PULMONARY FIBROSIS | NHS ENGLAND |
PIXANTRONE | CANCER NHL |
NHS ENGLAND |
PLATELET LYSATE THERAPY | NHS ENGLAND | |
PLERIXAFOR | STEM CELL MOBILISATION | NHS ENGLAND |
PLERIXAFOR | STEM CELL MOBILISATION | NHS ENGLAND |
POLATUZUMAB VEDOTIN | CANCER B-cell lymphoma |
NHS ENGLAND |
POLATUZUMAB VEDOTIN | CANCER B-cell lymphoma |
NHS ENGLAND |
POMALIDOMIDE | CANCER MM |
NHS ENGLAND |
POMALIDOMIDE | CANCER MM |
NHS ENGLAND |
POMALIDOMIDE | CANCER MM |
NHS ENGLAND |
POMALIDOMIDE | MYELOFIBROSIS | NHS ENGLAND |
PONATINIB | CANCER ALL |
NHS ENGLAND |
PONESIMOD | MULTIPLE SCLEROSIS | NHS ENGLAND |
POSACONAZOLE | FUNGAL INFECTION | NHS ENGLAND |
PRALSETINIB | CANCER Lung cancer |
NHS ENGLAND |
PRETOMANID | TB | NHS ENGLAND |
PROTEIN C HUMAN (acute use) | FOR SPECIALISED INDICATIONS | NHS ENGLAND |
PROTEIN C HUMAN (long-term use) | FOR SPECIALISED INDICATIONS | NHS ENGLAND |
PROTEIN KINASE INHIBITORS | ENDOCRINOLOGY; NON-MALIGNANT CONDITIONS | NHS ENGLAND |
PROTHROMBIN COMPLEX CONCENTRATE (PCC) | AS PER BCSH GUIDELINES FOR SPECIALISED INDICATIONS | NHS ENGLAND |
QUIZARTINIB | CANCER AML |
CDF |
QUIZARTINIB | CANCER AML |
NHS ENGLAND |
RADIUM-223 DICHLORIDE | CANCER Prostate cancer |
NHS ENGLAND |
RALTEGRAVIR | HIV IN COMBINATION WITH OTHER ANTI-RETROVIRAL DRUGS | NHS ENGLAND |
RAMUCIRUMAB | CANCER Gastric or gastro-oesophageal adenocarcinoma |
NHS ENGLAND |
RAMUCIRUMAB | CANCER Lung cancer |
NHS ENGLAND |
RANIBIZUMAB | RETINOPATHY OF PREMATURITY | NHS ENGLAND |
Ranibizumab (Lucentis®/ Ongavia®) | Macular oedema (Retinal vein occlusion) | ICB |
Ranibizumab (Lucentis®/ Ongavia®) | Diabetic Macular Oedema | ICB |
Ranibizumab (Lucentis®/ Ongavia®) | Macular degeneration(wet age-related) | ICB |
Ranibizumab (Lucentis®/ Ongavia®) | Choroidal neovascularisation (CNV) associated with pathological myopia | ICB |
RASBURICASE | HYPERURICAEMIA | NHS ENGLAND |
RAVULIZUMAB | AHUS | NHS ENGLAND |
RAVULIZUMAB | PAROXYSMAL NOCTURNAL HAEMOGLOBINURIA | NHS ENGLAND |
REGORAFENIB | CANCER Colorectal cancer |
NHS ENGLAND |
REGORAFENIB | CANCER Gastrointestinal stromal tumour |
NHS ENGLAND |
REGORAFENIB | CANCER Hepatocellular carcinoma |
NHS ENGLAND |
RELATLIMAB | CANCER Melanoma |
NHS ENGLAND |
Remdesivir (Veklury®) | Covid-19 | ICB |
REPARIXIN | PREVENTION OF DELAYED GRAFT FUNCTION | NHS ENGLAND |
RESLIZUMAB | ASTHMA | NHS ENGLAND |
REZAFUNGIN | FUNGAL INFECTION | NHS ENGLAND |
RIBOCICLIB | CANCER Breast cancer |
NHS ENGLAND |
RIBOCICLIB | CANCER Breast cancer |
NHS ENGLAND |
RILPIVIRINE | HIV IN COMBINATION WITH OTHER ANTI-RETROVIRAL DRUGS | NHS ENGLAND |
RILPIVIRINE | HIV IN COMBINATION WITH OTHER ANTI-RETROVIRAL DRUGS | NHS ENGLAND |
RILPIVIRINE | HIV IN COMBINATION WITH OTHER ANTI-RETROVIRAL DRUGS | NHS ENGLAND |
Rimegepant (Vydura®) | treating migraine | ICB |
Rimegepant (Vydura®) | preventing Migraine | ICB |
RIOCIGUAT | PULMONARY ARTERIAL HYPERTENSION | NHS ENGLAND |
RIOCIGUAT | PULMONARY ARTERIAL HYPERTENSION (CTEPH) | NHS ENGLAND |
RIPRETINIB | CANCER Gastrointestinal stromal tumour |
NHS ENGLAND |
RISANKIZUMAB | CROHN'S DISEASE (ADOLESCENTS 16 - 17 YEARS) | NHS ENGLAND |
Risankizumab (Skyrizi®) | Ulcerative colitis | ICB |
Risankizumab (Skyrizi®) | Psoriatic Arthritis | ICB |
Risankizumab (Skyrizi®) | Crohn's disease | ICB |
Risankizumab (Skyrizi®) | Moderate to severe plaque psoriasis | ICB |
RISDIPLAM | SPINAL MUSCULAR ATROPHY | NHS ENGLAND |
Ritlecitinib (Litfulo®) | Severe Alopecia areata | ICB |
RITONAVIR | HIV IN COMBINATION WITH OTHER ANTI-RETROVIRAL DRUGS | NHS ENGLAND |
RITUXIMAB | ABO-INCOMPATIBLE KIDNEY TRANSPLANTS | NHS ENGLAND |
RITUXIMAB | ACQUIRED HAEMOPHILIA | NHS ENGLAND |
RITUXIMAB | ANCA-ASSOCIATED VASCULITIS | NHS ENGLAND |
RITUXIMAB | ANCA-ASSOCIATED VASCULITIS | NHS ENGLAND |
RITUXIMAB | BEHCETS SYNDROME | NHS ENGLAND |
RITUXIMAB | ANTI-NMDAR AUTOIMMUNE ENCEPHALITIS | NHS ENGLAND |
RITUXIMAB | CASTLEMAN'S DISEASE | NHS ENGLAND |
RITUXIMAB | CHRONIC GRAFT VERSUS HOST DISEASE | NHS ENGLAND |
RITUXIMAB | CHRONIC INFLAMMATORY DEMYELINATING POLYNEUROPATHY | NHS ENGLAND |
RITUXIMAB | CONNECTIVE TISSUE DISEASE - INTERSTITIAL LUNG DISEASE | NHS ENGLAND |
RITUXIMAB | CYTOPENIA COMPLICATING PRIMARY IMMUNODEFICIENCY | NHS ENGLAND |
RITUXIMAB | DELAYED HAEMOLYTIC TRANSFUSION REACTIONS AND HYPERHAEMOLYSIS IN PATIENTS WITH HAEMOGLOBINOPATHIES | NHS ENGLAND |
RITUXIMAB | DERMATOMYOSITIS AND POLYMYOSITIS (ADULTS) | NHS ENGLAND |
RITUXIMAB | FOCAL SEGMENTAL GLOMERULOSCLEROSIS | NHS ENGLAND |
RITUXIMAB | IDIOPATHIC MEMBRANOUS NEPHROPATHY | NHS ENGLAND |
RITUXIMAB | IGM PARAPROTEINAEMIC DEMYELINATING PERIPHERAL NEUROPATHY | NHS ENGLAND |
RITUXIMAB | IMMUNOBULLOUS DISEASE | NHS ENGLAND |
RITUXIMAB | IMMUNOGLOBIN G4 RELATED DISEASE | NHS ENGLAND |
RITUXIMAB | JUVENILE IDIOPATHIC ARTHRITIS - PAEDIATRICS | NHS ENGLAND |
RITUXIMAB | MULTIFOCAL MOTOR NEUROPATHY | NHS ENGLAND |
RITUXIMAB | MYASTHENIA GRAVIS | NHS ENGLAND |
RITUXIMAB | NEUROMYELITIS OPTICA | NHS ENGLAND |
RITUXIMAB | NODAL/PARANODAL ANTIBODY POSITIVE INFLAMMATORY AUTOIMMUNE NEUROPATHY | NHS ENGLAND |
RITUXIMAB | PEMPHIGUS VULGARIS AND PEMPHIGOID DISEASE | NHS ENGLAND |
RITUXIMAB | PRIMARY SJOGREN'S SYNDROME (PSS) | NHS ENGLAND |
RITUXIMAB | STEROID RESISTANT NEPHROTIC SYNDROME - PAEDIATRICS | NHS ENGLAND |
RITUXIMAB | STEROID SENSITIVE NEPHROTIC SYNDROME | NHS ENGLAND |
RITUXIMAB | SYSTEMIC LUPUS ERYTHEMATOSUS (SLE) | NHS ENGLAND |
RITUXIMAB | THROMBOTIC THROMBOCYTOPENIC PURPURA | NHS ENGLAND |
RITUXIMAB | VASCULITIS OF THE PERIPHERAL NERVOUS SYSTEM | NHS ENGLAND |
Rituximab (Mabthera®, Truxima ®, Rixathon ®) | Rheumatoid Arthritis | ICB |
Rituximab (Mabthera®, Truxima ®, Rixathon ®) | Immune (idiopathic) thrombocytopenic purpura (ITP) | ICB |
RITUXIMAB IV | CANCER | NHS ENGLAND |
RITUXIMAB IV | CANCER ALL |
NHS ENGLAND |
RITUXIMAB IV | CANCER B-cell lymphoma |
NHS ENGLAND |
RITUXIMAB IV | CANCER CLL |
NHS ENGLAND |
RITUXIMAB IV | CANCER CLL |
NHS ENGLAND |
RITUXIMAB IV | CANCER CLL |
NHS ENGLAND |
RITUXIMAB IV | CANCER Follicular lymphoma |
NHS ENGLAND |
RITUXIMAB IV | CANCER Follicular lymphoma |
NHS ENGLAND |
RITUXIMAB IV | CANCER NHL |
NHS ENGLAND |
RITUXIMAB IV | CANCER NHL |
NHS ENGLAND |
RITUXIMAB SUBCUTANEOUS FORMULATION | CANCER Follicular lymphoma |
NHS ENGLAND |
RIVIPANSEL SODIUM | HEPATIC VENO-OCCLUSIVE DISEASE | NHS ENGLAND |
RIVIPANSEL SODIUM | SICKLE CELL DISEASE | NHS ENGLAND |
Romiplostim (Nplate®) | Thrombocytopenia purpura | ICB |
Romosozumab (Evenity®) | Osteoporosis | ICB |
ROPEGINTERFERON ALFA-2b | HEPATITIS C | NHS ENGLAND |
ROPEGINTERFERON ALFA-2b | MYELOPROLIFERATIVE NEOPLASMS | NHS ENGLAND |
Roxadustat | Symptomatic anaemia in chronic kidney disease | ICB |
RP-L102 | FANCONI ANAEMA | NHS ENGLAND |
RP-L201 | LEUKOCYTE ADHESION DEFICIENCY-1 (LAD-1) | NHS ENGLAND |
RUCAPARIB | CANCER Ovarian, fallopian tube and peritoneal cancer |
CDF |
RUCAPARIB | CANCER Ovarian, fallopian tube and peritoneal cancer |
CDF |
RUCAPARIB | CANCER Ovarian, fallopian tube and peritoneal cancer |
NHS ENGLAND |
RURIOCTOCOG ALFA PEGOL (FACTOR VIII - recombinant) |
HAEMOPHILIA A | NHS ENGLAND |
RUXOLITINIB | CANCER Polycythaemia vera |
NHS ENGLAND |
RUXOLITINIB | CANCER Myelofibrosis |
NHS ENGLAND |
SACITUZUMAB GOVITECAN | CANCER Breast cancer |
NHS ENGLAND |
SAPROPTERIN | ADULTS AND CHILDREN WITH PHENYLKETONURIA | NHS ENGLAND |
SAPROPTERIN | ADULTS AND CHILDREN WITH PHENYLKETONURIA | NHS ENGLAND |
SAPROPTERIN | ADULTS AND CHILDREN WITH PHENYLKETONURIA | NHS ENGLAND |
SAPROPTERIN | ADULTS AND CHILDREN WITH TETRAHYDROBIOPTERIN DISORDERS | NHS ENGLAND |
SAQUINAVIR | HIV IN COMBINATION WITH OTHER ANTI-RETROVIRAL DRUGS | NHS ENGLAND |
Sarilumab (Kevzara®) | Rheumatoid Arthritis | ICB |
SATRALIZUMAB | NEUROMYELITIS OPTICA | NHS ENGLAND |
SEBELIPASE ALFA | WOLMAN DISEASE | NHS ENGLAND |
SECUKINUMAB | PLAQUE PSORIASIS - PAEDIATRICS | NHS ENGLAND |
SECUKINUMAB | HIDRADENITIS SUPPURATIVA | NHS ENGLAND |
Secukinumab (Cosentyx®) | Ankylosing spondylitis | ICB |
Secukinumab (Cosentyx®) | Moderate to severe plaque psoriasis | ICB |
Secukinumab (Cosentyx®) | Non-radiographic axial spondyloarthritis | ICB |
Secukinumab (Cosentyx®) | Psoriatic Arthritis | ICB |
SELEXIPAG | PULMONARY ARTERIAL HYPERTENSION | NHS ENGLAND |
SELINEXOR | CANCER MM |
NHS ENGLAND |
SELINEXOR | CANCER MM |
NHS ENGLAND |
SELPERCATINIB | CANCER Lung cancer |
CDF |
SELPERCATINIB | CANCER Lung cancer |
CDF |
SELPERCATINIB | CANCER Thyroid cancer |
CDF |
SELPERCATINIB | CANCER Thyroid cancer |
CDF |
SELPERCATINIB | CANCER Thyroid cancer |
CDF |
SELUMETINIB | TYPE 1 (NF-1) IN CHILDREN WHO HAVE SYMPTOMATIC, INOPERABLE PLEXIFORM NEUROFIBROMAS (PN) | NHS ENGLAND |
SETMELANOTIDE | LEPTIN DEFICIENCY | NHS ENGLAND |
SETMELANOTIDE | BARDET-BIEDL SYNDROME | NHS ENGLAND |
SETRUSUMAB | OSTEOGENESIS IMPERFECTA | NHS ENGLAND |
SILDENAFIL | PULMONARY ARTERIAL HYPERTENSION | NHS ENGLAND |
SILDENAFIL | PULMONARY ARTERIAL HYPERTENSION | NHS ENGLAND |
SILTUXIMAB | CASTLEMAN'S DISEASE | NHS ENGLAND |
SIMOCTOCOG ALFA (FACTOR VIII - recombinant) |
HAEMOPHILIA A | NHS ENGLAND |
SIPONIMOD | MULTIPLE SCLEROSIS | NHS ENGLAND |
SIROLIMUS | LYMPHANGIOLEIOMYOMATOSIS | NHS ENGLAND |
SIROLIMUS | KIDNEY TRANSPLANT - ADULTS | NHS ENGLAND |
SIROLIMUS | KIDNEY TRANSPLANT - CHILDREN & YOUNG PEOPLE | NHS ENGLAND |
SIROLIMUS | TRANSPLANT IMMUNOSUPPRESSION ONLY - ADULTS | NHS ENGLAND |
SIROLIMUS | TRANSPLANT IMMUNOSUPPRESSION ONLY - CHILDREN & YOUNG PEOPLE | NHS ENGLAND |
SITOIGANAP | CANCER Glioma |
NHS ENGLAND |
SODIUM BENZOATE | UREA CYCLE DISORDERS | NHS ENGLAND |
SODIUM HYDROXYBUTYRATE | UREA CYCLE DISORDERS | NHS ENGLAND |
SODIUM OXYBATE | NARCOLEPSY - PAEDIATRICS | NHS ENGLAND |
SODIUM PHENYLBUTYRATE | UREA CYCLE DISORDERS | NHS ENGLAND |
SODIUM THIOSULFATE | PREVENTION OF HEARING LOSS SECONDARY TO CISPLATIN CHEMOTHERAPY IN CHILDREN | NHS ENGLAND |
SOFOSBUVIR + LEDIPASVIR +/- RIBAVIRIN | HEPATITIS C | NHS ENGLAND |
SOFOSBUVIR + PEGINTERFERON + RIBAVIRIN | HEPATITIS C | NHS ENGLAND |
SOFOSBUVIR + VELPATASVIR | HEPATITIS C | NHS ENGLAND |
SOFOSBUVIR + VELPATASVIR + VOXILAPREVIR | HEPATITIS C | NHS ENGLAND |
Somatrogon (Ngenla®) | Growth Failure | ICB |
SORAFENIB | CANCER AML |
NHS ENGLAND |
SORAFENIB | CANCER Hepatocellular carcinoma |
NHS ENGLAND |
SORAFENIB | CANCER Thyroid cancer |
NHS ENGLAND |
SOTATERCEPT | PULMONARY ARTERIAL HYPERTENSION | NHS ENGLAND |
SOTORASIB | CANCER Lung cancer |
CDF |
Sotrivimab (Xevudy®) | Covid-19 | ICB |
STAVUDINE | HIV IN COMBINATION WITH OTHER ANTI-RETROVIRAL DRUGS | NHS ENGLAND |
STRIMVELIS AUTOLOGOUS CD34+ ENRICHED CELL FRACTION THAT CONTAINS CD34+ CELLS TRANSDUCED WITH RETROVIRAL VECTOR THAT ENCODES FOR THE HUMAN ADA cDNA SEQUENCE |
ADENOSINE DEAMINASE DEFICIENCY-SEVERE COMBINED IMMUNODEFICIENCY | NHS ENGLAND |
SUCROFERRIC OXYHYDROXIDE | ADULT RENAL DIALYSIS ONLY | NHS ENGLAND |
SUNITINIB | CANCER Gastrointestinal stromal tumour |
NHS ENGLAND |
SUNITINIB | CANCER Neuroendocrine tumour |
NHS ENGLAND |
SUNITINIB | CANCER Renal cell carcinoma |
NHS ENGLAND |
SUSOCTOCOG ALFA (FACTOR VIII - porcine recombinant) |
ACQUIRED HAEMOPHILIA A | NHS ENGLAND |
SUTIMLIMAB | PRIMARY COLD AGGLUTININ DISEASE | NHS ENGLAND |
TABELECLEUCEL | CANCER Posttransplant lymphoproliferative disorder |
NHS ENGLAND |
TACROLIMUS | KIDNEY TRANSPLANT - ADULTS | NHS ENGLAND |
TACROLIMUS | KIDNEY TRANSPLANT - CHILDREN & YOUNG PEOPLE | NHS ENGLAND |
TACROLIMUS | TRANSPLANT IMMUNOSUPPRESSION ONLY | NHS ENGLAND |
TADALAFIL | PULMONARY ARTERIAL HYPERTENSION | NHS ENGLAND |
TADALAFIL | PULMONARY ARTERIAL HYPERTENSION | NHS ENGLAND |
TAFAMIDIS | AMYLOIDOSIS | NHS ENGLAND |
TAFASITAMAB | CANCER B-cell lymphoma |
NHS ENGLAND |
TAGRAXOFUSP | CANCER Dendritic cell neoplasm |
NHS ENGLAND |
TALAZOPARIB | CANCER Breast cancer |
NHS ENGLAND |
TALAZOPARIB | CANCER Prostate cancer |
NHS ENGLAND |
TALIMOGENE LAHERPAREPVEC | CANCER Melanoma |
NHS ENGLAND |
Targeted-release budesonide (Kinpeygo®) | Primary IgA nephropathy | ICB |
TASONERMIN | CANCER | NHS ENGLAND |
TEBENTAFUSP | CANCER Uveal melanoma |
CDF |
TECLISTAMAB | CANCER MM |
CDF |
TECLISTAMAB | CANCER MM |
NHS ENGLAND |
TEDUGLUTIDE | SHORT BOWEL SYNDROME | NHS ENGLAND |
TELBIVUDINE | HEPATITIS B | NHS ENGLAND |
TELOTRISTAT | CARCINOID SYNDROME DIARRHOEA | NHS ENGLAND |
TEMOZOLOMIDE | CANCER Astrocytoma |
NHS ENGLAND |
TEMOZOLOMIDE | CANCER Glioma |
NHS ENGLAND |
TEMOZOLOMIDE | CANCER Glioma |
NHS ENGLAND |
TEMOZOLOMIDE | ENDOCRINOLOGY; NON-MALIGNANT CONDITIONS | NHS ENGLAND |
TEMSIROLIMUS | CANCER Renal cell carcinoma |
NHS ENGLAND |
TENOFOVIR | HIV IN COMBINATION WITH OTHER ANTI-RETROVIRAL DRUGS | NHS ENGLAND |
TENOFOVIR | HIV IN COMBINATION WITH OTHER ANTI-RETROVIRAL DRUGS | NHS ENGLAND |
TENOFOVIR ALAFENAMIDE | HEPATITIS B | NHS ENGLAND |
TENOFOVIR ALAFENAMIDE | HIV IN COMBINATION WITH OTHER ANTI-RETROVIRAL DRUGS | NHS ENGLAND |
TENOFOVIR ALAFENAMIDE | HIV IN COMBINATION WITH OTHER ANTI-RETROVIRAL DRUGS | NHS ENGLAND |
TENOFOVIR ALAFENAMIDE | HIV IN COMBINATION WITH OTHER ANTI-RETROVIRAL DRUGS | NHS ENGLAND |
TENOFOVIR ALAFENAMIDE | HIV IN COMBINATION WITH OTHER ANTI-RETROVIRAL DRUGS | NHS ENGLAND |
TENOFOVIR ALAFENAMIDE | HIV IN COMBINATION WITH OTHER ANTI-RETROVIRAL DRUGS | NHS ENGLAND |
TENOFOVIR DISOPROXIL | HEPATITIS B +/- OTHER ANTI-RETROVIRAL DRUGS | NHS ENGLAND |
TENOFOVIR DISOPROXIL | HIV IN COMBINATION WITH OTHER ANTI-RETROVIRAL DRUGS | NHS ENGLAND |
TENOFOVIR DISOPROXIL | HIV IN COMBINATION WITH OTHER ANTI-RETROVIRAL DRUGS | NHS ENGLAND |
TENOFOVIR DISOPROXIL | HIV IN COMBINATION WITH OTHER ANTI-RETROVIRAL DRUGS | NHS ENGLAND |
TEPOTINIB | CANCER Lung cancer |
NHS ENGLAND |
TEPRASIRAN | PREVENTION OF DELAYED GRAFT FUNCTION | NHS ENGLAND |
TEPROTUMUMAB | GRAVES ORBITOPATHY | NHS ENGLAND |
TERIFLUNOMIDE | MULTIPLE SCLEROSIS | NHS ENGLAND |
TERIFLUNOMIDE | MULTIPLE SCLEROSIS | NHS ENGLAND |
TEZACAFTOR + IVACAFTOR | CYSTIC FIBROSIS | NHS ENGLAND |
TEZACAFTOR + IVACAFTOR | CYSTIC FIBROSIS | NHS ENGLAND |
TEZEPELUMAB | ASTHMA | NHS ENGLAND |
THALIDOMIDE | CANCER MM |
NHS ENGLAND |
THROMBOMODULIN, RECOMBINANT HUMAN | PSEUDOANEURYSM | NHS ENGLAND |
TIDEGLUSIB | CONGENITAL MYOTONIC DYSTROPHY | NHS ENGLAND |
Tildrakizumab (Ilumetri®) | Moderate to severe plaque psoriasis | ICB |
TIPRANAVIR | HIV IN COMBINATION WITH OTHER ANTI-RETROVIRAL DRUGS | NHS ENGLAND |
TISAGENLECLEUCEL | CANCER ALL |
NHS ENGLAND |
TISAGENLECLEUCEL | CANCER B-cell lymphoma |
NHS ENGLAND |
TIVOZANIB | CANCER Renal cell carcinoma |
NHS ENGLAND |
TOBRAMYCIN | CYSTIC FIBROSIS | NHS ENGLAND |
TOBRAMYCIN | CYSTIC FIBROSIS | NHS ENGLAND |
TOCILIZUMAB | ADULT ONSET STILLS DISEASE | NHS ENGLAND |
TOCILIZUMAB | CASTLEMAN'S DISEASE | NHS ENGLAND |
TOCILIZUMAB | CYTOKINE RELEASE SYNDROME FOLLOWING CAR-T OR BISPECIFIC ANTIBODY TREATMENT | NHS ENGLAND |
TOCILIZUMAB | GIANT CELL ARTERITIS | NHS ENGLAND |
TOCILIZUMAB | JUVENILE IDIOPATHIC ARTHRITIS - PAEDIATRICS | NHS ENGLAND |
TOCILIZUMAB | JUVENILE IDIOPATHIC ARTHRITIS - PAEDIATRICS | NHS ENGLAND |
TOCILIZUMAB | TAKAYASU ARTERITIS | NHS ENGLAND |
Tocilizumab (Tyenne®, RoActemra®) | Covid-19 | ICB |
Tocilizumab (Tyenne®, RoActemra®) | Rheumatoid Arthritis | ICB |
Tocilizumab (Tyenne®, RoActemra®) | Juvenile arthritis (adult) | ICB |
TOFACITINIB | JUVENILE IDIOPATHIC ARTHRITIS - PAEDIATRICS | NHS ENGLAND |
Tofacitinib (Xeljanz®) | Rheumatoid Arthritis | ICB |
Tofacitinib (Xeljanz®) | Psoriatic Arthritis | ICB |
Tofacitinib (Xeljanz®) | Moderately to severe ulceratve colitis | ICB |
Tofacitinib (Xeljanz®) | Ankylosing spondylitis | ICB |
Tofacitinib (Xeljanz®) | Juvenile Idiopathic arthritis (adult only) | ICB |
TOFERSEN SODIUM | AMYOTROPHIC LATERAL SCLEROSIS (MOTOR NEURONE DISEASE) | NHS ENGLAND |
TOLVAPTAN | HYPONATRAEMIA IN CANCER | NHS ENGLAND |
Tolvaptan (Samsca®) | Autosomal dominant polycystic kidney disease | ICB |
TORIPALIMAB | CANCER Oesophageal cancer |
NHS ENGLAND |
TRABECTEDIN | CANCER Sarcoma |
NHS ENGLAND |
TRALOKINUMAB | ASTHMA | NHS ENGLAND |
Tralokinumab (Adtralza®) | Moderate to severe atopic dermatitis | ICB |
TRAMETINIB | CANCER Glioma |
NHS ENGLAND |
TRAMETINIB | CANCER Lung cancer |
NHS ENGLAND |
TRAMETINIB | CANCER Melanoma |
NHS ENGLAND |
TRAMETINIB | CANCER Melanoma |
NHS ENGLAND |
TRAMETINIB | CANCER Ovarian cancer |
NHS ENGLAND |
TRAMETINIB | CANCER Thyroid cancer |
NHS ENGLAND |
TRASTUZUMAB | CANCER Breast cancer |
NHS ENGLAND |
TRASTUZUMAB | CANCER Breast cancer |
NHS ENGLAND |
TRASTUZUMAB | CANCER Breast cancer |
NHS ENGLAND |
TRASTUZUMAB | CANCER Gastric cancer |
NHS ENGLAND |
TRASTUZUMAB DERUXTECAN | CANCER Breast cancer |
CDF |
TRASTUZUMAB DERUXTECAN | CANCER Breast cancer |
NHS ENGLAND |
TRASTUZUMAB DERUXTECAN | CANCER Gastric or gastro-esophageal junction cancer |
NHS ENGLAND |
TRASTUZUMAB EMTANSINE | CANCER Breast cancer |
NHS ENGLAND |
TRASTUZUMAB EMTANSINE | CANCER Breast cancer |
NHS ENGLAND |
TREOSULFAN | CANCER | NHS ENGLAND |
TREPROSTINIL SODIUM | PULMONARY ARTERIAL HYPERTENSION | NHS ENGLAND |
TRIENTINE | WILSONS DISEASE | NHS ENGLAND |
TRIFLURIDINE-TIPIRACIL | CANCER Colorectal cancer |
NHS ENGLAND |
TRIFLURIDINE-TIPIRACIL | CANCER Colorectal cancer |
NHS ENGLAND |
TRIFLURIDINE-TIPIRACIL | CANCER Gastric or gastro-oesophageal adenocarcinoma |
NHS ENGLAND |
TRIHEPTANOIN | PYRUVATE CARBOXYLASE DEFICIENCY | NHS ENGLAND |
TUCATINIB | CANCER Breast cancer |
NHS ENGLAND |
TUROCTOCOG ALFA (FACTOR VIII - recombinant) |
HAEMOPHILIA A | NHS ENGLAND |
TUROCTOCOG ALFA PEGOL (FACTOR VIII - recombinant) |
HAEMOPHILIA A | NHS ENGLAND |
UBLITUXIMAB | MULTIPLE SCLEROSIS | IMF |
UBLITUXIMAB | MULTIPLE SCLEROSIS | NHS ENGLAND |
UPADACITINIB | MODERATE TO SEVERE ATOPIC DERMATITIS - PAEDIATRICS | NHS ENGLAND |
Upadacitinib (Rinvoq®) | Crohn's disease | ICB |
Upadacitinib (Rinvoq®) | Ulcerative Colitis | ICB |
Upadacitinib (Rinvoq®) | Non-radiographic axial spondyloarthritis | ICB |
Upadacitinib (Rinvoq®) | Moderate to severe atopic dermatitis | ICB |
Upadacitinib (Rinvoq®) | Ankylosing spondylitis | ICB |
Upadacitinib (Rinvoq®) | Psoriatic Arthritis | ICB |
Upadacitinib (Rinvoq®) | Rheumatoid Arthritis | ICB |
URIDINE TRIACETATE | TREATMENT OF TOXICITY WITH 5-FU AND CAPECITABINE | NHS ENGLAND |
USTEKINUMAB | CROHN'S DISEASE - REFRACTORY IN PRE-PUBESCENT CHILDREN - PAEDIATRICS | NHS ENGLAND |
USTEKINUMAB | PLAQUE PSORIASIS - PAEDIATRICS | NHS ENGLAND |
Ustekinumab (Pyzchiva ®, Uzpruvo® ,Stelara®) | Psoriasis | ICB |
Ustekinumab (Pyzchiva ®, Uzpruvo® ,Stelara®) | Psoriatic Arthritis | ICB |
Ustekinumab (Pyzchiva ®, Uzpruvo® ,Stelara®) | Crohn’s disease | ICB |
Ustekinumab (Pyzchiva ®, Uzpruvo® ,Stelara®) | Ulcerative Colitis (moderate to severe) | ICB |
VADADUSTAT | DIALYSIS-INDUCED ANAEMIA | NHS ENGLAND |
VALOCTOCOGENE ROXAPARVOVEC | HAEMOPHILIA A | NHS ENGLAND |
VAMOROLONE | DUCHENNE MUSCULAR DYSTROPHY | NHS ENGLAND |
VANDETANIB | CANCER Thyroid cancer |
NHS ENGLAND |
VATIQUINONE | FRIEDREICHS ATAXIA | NHS ENGLAND |
VEDOLIZUMAB | ULCERATIVE COLITIS - REFRACTORY IN PRE-PUBESCENT CHILDREN - PAEDIATRICS | NHS ENGLAND |
Vedolizumab (Entyvio®) | Ulcerative Colitis (moderate to severe) | ICB |
Vedolizumab (Entyvio®) | Crohn’s disease | ICB |
VELAGLUCERASE ALFA | GAUCHER'S DISEASE | NHS ENGLAND |
VELMANASE ALFA | ALPHA MANNOSIDASE DEFICIENCY | NHS ENGLAND |
VEMURAFENIB | CANCER Melanoma |
NHS ENGLAND |
VENETOCLAX | CANCER CLL |
NHS ENGLAND |
VENETOCLAX | CANCER AML |
NHS ENGLAND |
VENETOCLAX | CANCER AML |
NHS ENGLAND |
VENETOCLAX | CANCER CLL |
NHS ENGLAND |
VENETOCLAX | CANCER CLL |
NHS ENGLAND |
VENETOCLAX | CANCER CLL |
NHS ENGLAND |
Verteporfin (Visudyne®) | Central serous chorioretinopathy | ICB |
Verteporfin (Visudyne®) | Polypoidal choroidal vasculopathy | ICB |
VESTRONIDASE ALFA | MUCOPOLYSACCHARIDOSIS VII | NHS ENGLAND |
VISMODEGIB | CANCER Basal cell carcinoma |
NHS ENGLAND |
VOCLOSPORIN | LUPUS NEPHRITIS | NHS ENGLAND |
VOLANESORSEN | FAMILIAL CHYLOMICRONEMIA SYNDROME | NHS ENGLAND |
VON WILLEBRAND FACTOR (VON WILLEBRAND FACTOR - plasma derived) |
VON WILLEBRAND DEFICIENCY | NHS ENGLAND |
VONICOG ALFA (VON WILLEBRAND FACTOR - recombinant) |
VON WILLEBRAND DEFICIENCY | NHS ENGLAND |
VORETIGENE NEPARVOVEC | INHERITED RETINAL DISORDER | NHS ENGLAND |
VORICONAZOLE | CHRONIC PULMONARY ASPERGILLOSIS | NHS ENGLAND |
VORICONAZOLE | FUNGAL INFECTION | NHS ENGLAND |
VUTRISIRAN | AMYLOIDOSIS | NHS ENGLAND |
ZANUBRUTINIB | CANCER Waldenstrom's macroglobulinaemia |
NHS ENGLAND |
ZANUBRUTINIB | CANCER CLL |
NHS ENGLAND |
ZANUBRUTINIB | CANCER Lymphoma |
NHS ENGLAND |
ZIDOVUDINE | HIV IN COMBINATION WITH OTHER ANTI-RETROVIRAL DRUGS | NHS ENGLAND |
ZILUCOPLAN | MYASTHENIA GRAVIS | NHS ENGLAND |
- First Line Choice
- On Formulary
- Specialist Initiation Only
- Hospital Only
- KMPT Initiation Only